https://www.sobi.com/en/congresses 2026-10-14T14:14:30+02:00 0.5 https://www.sobi.com/en/medical-grant 2026-10-13T10:40:34+02:00 0.5 https://www.sobi.com/en/investors 2026-10-08T13:03:11+02:00 0.5 https://www.sobi.com/en 2026-10-08T13:01:56+02:00 daily 1.0 https://www.sobi.com/en/therapeutic-areas 2026-10-07T14:02:10+02:00 0.5 https://www.sobi.com/en/meet-our-employees 2026-10-06T11:13:16+02:00 0.5 https://www.sobi.com/en/report-side-effect 2026-10-06T10:29:21+02:00 0.5 https://www.sobi.com/en/haematology 2026-10-05T15:58:35+02:00 0.5 https://www.sobi.com/en/investigator-sponsored-studies 2026-10-05T09:53:27+02:00 0.5 https://www.sobi.com/en/news-releases/c3g-awareness-day-listening-voices-behind-diagnosis 2026-09-29T16:18:32+02:00 0.5 https://www.sobi.com/en/familial-chylomicronemia-syndrome-fcs 2026-09-25T09:53:44+02:00 0.5 https://www.sobi.com/en/news-releases/building-resilient-approach-haemophilia-care-trinidad-and-tobago 2026-09-25T08:43:28+02:00 0.5 https://www.sobi.com/en/contacts 2026-09-16T10:23:28+02:00 0.5 https://www.sobi.com/en/disclosure-payments-healthcare 2026-09-15T16:32:05+02:00 0.5 https://www.sobi.com/en/presentations 2026-09-15T10:29:53+02:00 0.5 https://www.sobi.com/en/medicines 2026-06-08T16:17:21+02:00 0.5 https://www.sobi.com/en/focus-rare-diseases 2026-09-09T15:26:11+02:00 0.5 https://www.sobi.com/en/committees 2026-09-07T11:36:38+02:00 0.5 https://www.sobi.com/en/haemophagocytic-lymphohistiocytosis-hlh 2026-09-07T10:03:21+02:00 0.5 https://www.sobi.com/en/stills-disease 2026-09-04T13:29:46+02:00 0.5 https://www.sobi.com/en/diffuse-large-b-cell-lymphoma 2026-08-28T11:15:56+02:00 0.5 https://www.sobi.com/en/analyst-coverage 2026-08-27T09:31:13+02:00 0.5 https://www.sobi.com/en/stories/living-beyond-dlbcl-facing-fear-relapse 2026-08-25T14:28:33+02:00 0.5 https://www.sobi.com/en/news-releases/sobi-ranks-no-1-again-patient-engagement-rare-diseases 2026-08-20T10:44:13+02:00 0.5 https://www.sobi.com/en/our-environmental-footprint 2026-08-12T08:57:58+02:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/delarsrapport-andra-kvartalet-2026-betydande-tillvaxt-med-viktiga-framsteg-i-pipeline 2026-07-17T17:05:15+02:00 0.5 https://www.sobi.com/en/financial-reports/sobi-q2-2026-report-significant-growth-important-pipeline-progress 2026-07-17T17:00:55+02:00 0.5 https://www.sobi.com/en/pipeline 2026-07-15T12:50:33+02:00 0.5 https://www.sobi.com/en/commitment-patients 2026-07-13T10:32:06+02:00 0.5 https://www.sobi.com/en/policies-and-responsibilities 2026-07-13T10:29:28+02:00 0.5 https://www.sobi.com/en/news-releases/sobi-recognised-number-one-bleeding-disorders-report 2026-07-10T08:01:56+02:00 0.5 https://www.sobi.com/en/hereditary-transthyretin-amyloidosis-hattr 2026-07-09T12:00:50+02:00 0.5 https://www.sobi.com/en/specialty-care 2026-06-26T14:53:12+02:00 0.5 https://www.sobi.com/en/innovation 2026-07-08T09:00:13+02:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/delarsrapport-forsta-kvartalet-2026 2026-07-07T10:39:58+02:00 0.5 https://www.sobi.com/en/financial-reports/interim-report-q1-2026 2026-07-07T10:37:18+02:00 0.5 https://www.sobi.com/en/research-development 2026-07-06T18:51:52+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-har-mottagit-kompletteringsbegaran-complete-response-letter-fran-fda-nasp-nanoencapsulated-sirolimus-plus-pegadricase-2465071 2026-06-29T11:05:16+02:00 0.5 https://www.sobi.com/en/supporting-patient-organisations 2026-06-26T11:20:28+02:00 0.5 https://www.sobi.com/en/cryopyrin-associated-periodic-syndromes-caps 2026-06-26T11:16:34+02:00 0.5 https://www.sobi.com/en/sobi-itp-immune-thrombocytopenia 2026-06-26T11:04:32+02:00 0.5 https://www.sobi.com/en/hereditary-tyrosinaemia-type-1-ht-1 2026-06-26T10:54:58+02:00 0.5 https://www.sobi.com/en/sustainability-gov 2026-06-18T09:44:53+02:00 0.5 https://www.sobi.com/en/managed-access 2026-06-18T08:53:37+02:00 0.5 https://www.sobi.com/en/familial-mediterranean-fever-fmf 2026-06-08T14:14:51+02:00 0.5 https://www.sobi.com/en/news-releases/unite4rare-wins-2026-made-patients-award-systematic-meaningful-patient-engagement 2026-06-04T09:56:49+02:00 0.5 https://www.sobi.com/en/news-releases/adc-therapeutics-announces-results-lotis-5-phase-3-confirmatory-clinical-trial 2026-06-03T22:07:21+02:00 0.5 https://www.sobi.com/en/glance 2026-05-27T14:24:26+02:00 0.5 https://www.sobi.com/en/news-releases/sobi-recognised-one-worlds-most-impactful-companies-2026 2026-05-18T07:59:58+02:00 0.5 https://www.sobi.com/en/mtn-programme 2026-05-12T15:51:43+02:00 0.5 https://www.sobi.com/en/news-releases/sobi-puts-rare-kidney-disease-centre-stage-euronews-health-summit 2026-05-12T11:27:47+02:00 0.5 https://www.sobi.com/en/sustainability 2026-05-11T14:06:25+02:00 0.5 https://www.sobi.com/en/governance 2026-05-08T16:06:21+02:00 0.5 https://www.sobi.com/en/news-releases/sobi-recognised-sustainability-indices 2026-05-08T15:39:56+02:00 0.5 https://www.sobi.com/en/board-directors 2026-05-06T11:47:42+02:00 0.5 https://www.sobi.com/en/immunology 2026-04-30T09:08:33+02:00 0.5 https://www.sobi.com/en/news-releases/sobi-maintains-patient-engagement-position-corporate-reputation-pharma-report 2026-04-30T08:55:13+02:00 0.5 https://www.sobi.com/en/news-releases/unite4rare-sobi-strengthens-commitment-patients-and-caregivers-updated-tracking 2026-04-29T18:12:40+02:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/bokslutskommunike-2025 2026-04-28T09:01:54+02:00 0.5 https://www.sobi.com/en/financial-reports/interim-report-q4-2025 2026-04-28T09:01:06+02:00 0.5 https://www.sobi.com/en/press-releases 2026-04-23T09:28:42+02:00 0.5 https://www.sobi.com/en/news 2026-04-23T09:24:47+02:00 0.5 https://www.sobi.com/en/news-releases/sobi-marks-earth-day-strong-progress-science-based-climate-targets 2026-04-22T08:00:02+02:00 0.5 https://www.sobi.com/en/trusted-education-source 2026-04-21T14:06:38+02:00 0.5 https://www.sobi.com/en/humanitarian-programmes 2026-04-21T13:53:59+02:00 0.5 https://www.sobi.com/en/clinical-trials 2026-04-21T14:49:13+02:00 0.5 https://www.sobi.com/en/access-programmes 2026-04-21T14:42:54+02:00 0.5 https://www.sobi.com/en/patients-as-equal-contributors 2026-04-21T13:21:55+02:00 0.5 https://www.sobi.com/en/disease-awareness 2026-04-21T09:40:22+02:00 0.5 https://www.sobi.com/en/capability-building 2026-04-21T13:59:17+02:00 0.5 https://www.sobi.com/en/unite4rare 2026-04-20T13:21:48+02:00 0.5 https://www.sobi.com/en/value-added-services 2026-04-17T16:13:57+02:00 0.5 https://www.sobi.com/en/innovate-disease-awareness-campaigns 2026-04-17T16:11:29+02:00 0.5 https://www.sobi.com/en/patient-engagement-and-experience-data 2026-04-17T16:10:13+02:00 0.5 https://www.sobi.com/en/informed-decision-making 2026-04-17T16:06:21+02:00 0.5 https://www.sobi.com/en/define-and-deliver-on-shared-objectives 2026-04-17T16:03:23+02:00 0.5 https://www.sobi.com/en/continuous-and-transparent-communication 2026-04-17T15:56:07+02:00 0.5 https://www.sobi.com/en/patient-engagement-in-acquisitions 2026-04-17T15:23:25+02:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/sobi-publicerar-delarsrapport-forsta-kvartalet-2025-portfoljen-fortsatter-att-leverera 2026-04-10T11:40:30+02:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/sobi-publicerar-delarsrapport-andra-kvartalet-2025-fortsatt-starkt-momentum-i-portfolj-och-pipeline 2026-04-10T11:40:03+02:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/delarsrapport-jan-sep-2025 2026-04-10T11:39:31+02:00 0.5 https://www.sobi.com/en/sustainability-performance 2026-04-08T09:56:02+02:00 0.5 https://www.sobi.com/en/news-stories 2026-04-01T14:02:15+02:00 0.5 https://www.sobi.com/en/news-releases/billion-reasons-celebrate-expanding-access-haemophilia-treatment-worldwide 2026-04-02T12:13:06+02:00 0.5 https://www.sobi.com/en/stories/long-term-help-transforms-haemophilia-treatment-kenya 2026-04-02T09:16:50+02:00 0.5 https://www.sobi.com/en/stories/distributing-hope 2026-04-02T09:16:28+02:00 0.5 https://www.sobi.com/en/stories/safe-circumcision-program 2026-04-02T09:16:09+02:00 0.5 https://www.sobi.com/en/stories/changing-lives-in-vietnam 2026-04-02T09:15:44+02:00 0.5 https://www.sobi.com/en/stories/clinical-studies 2026-04-02T09:15:10+02:00 0.5 https://www.sobi.com/en/stories/sustainable-care-in-cambodia 2026-04-02T09:14:43+02:00 0.5 https://www.sobi.com/en/stories/sustainable-progress-dominican-republic-thanks-wfh-humanitarian-aid-program 2026-04-02T09:14:15+02:00 0.5 https://www.sobi.com/en/stories/decade-dedication-transforming-haemophilia-care-through-global-collaboration 2026-04-02T09:13:44+02:00 0.5 https://www.sobi.com/en/stories/liberate-life 2026-04-02T09:12:43+02:00 0.5 https://www.sobi.com/en/stories/steves-story 2026-04-02T09:12:23+02:00 0.5 https://www.sobi.com/en/stories/salomon 2026-04-02T09:11:35+02:00 0.5 https://www.sobi.com/en/stories/living-invisible-disease 2026-04-02T09:11:04+02:00 0.5 https://www.sobi.com/en/stories/changing-itp-together 2026-04-02T09:10:20+02:00 0.5 https://www.sobi.com/en/stories/living-itp 2026-04-02T09:09:57+02:00 0.5 https://www.sobi.com/en/stories/diagnose-diffuse-large-b-cell-lymphoma 2026-04-02T09:09:32+02:00 0.5 https://www.sobi.com/en/stories/living-diffuse-large-b-cell-lymphoma 2026-04-02T09:09:06+02:00 0.5 https://www.sobi.com/en/stories/new-therapys-path-patient 2026-04-02T08:58:29+02:00 0.5 https://www.sobi.com/en/news-releases/sobi-ranked-no-1-globally-rare-disease-corporate-reputation-according-patientviews-latest-survey 2026-04-01T16:15:44+02:00 0.5 https://www.sobi.com/en/news-releases/rare-kidney-disease-labyrinth-documentary-launch 2026-04-01T16:09:51+02:00 0.5 https://www.sobi.com/en/key-data 2026-03-31T15:38:21+02:00 0.5 https://www.sobi.com/en/access-treatment 2026-03-31T12:02:41+02:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/ars-och-hallbarhetsredovisning-2025 2026-03-31T11:06:28+02:00 0.5 https://www.sobi.com/en/financial-reports/annual-and-sustainability-report-2025 2026-03-31T11:06:21+02:00 0.5 https://www.sobi.com/en/financial-reports/interim-report-q3-2025 2026-03-30T16:05:02+02:00 0.5 https://www.sobi.com/en/financial-reports/sobi-publishes-q2-2025-report-continued-strong-portfolio-and-pipeline-momentum 2026-03-30T16:00:48+02:00 0.5 https://www.sobi.com/en/financial-reports/sobi-publishes-q1-2025-report-portfolio-continues-deliver 2026-03-30T16:00:04+02:00 0.5 https://www.sobi.com/en/capital-markets-day-2026 2026-02-24T16:37:25+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-capital-markets-day-2026-bringing-brilliant-ideas-life-and-building-next-chapter-ambition-deliver-sek-55bn-2030-2427315 2026-02-19T14:02:12+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobis-kapitalmarknadsdag-2026-bringing-brillant-ideas-life-med-ambitionen-att-na-55-miljarder-kronor-till-2030-inleder-vi-nasta 2026-02-19T14:01:09+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/bokslutskommunike-2021 2026-02-05T08:54:27+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/sobi-publicerar-delarsrapport-fjarde-kvartalet-och-bokslutskommunike-2022-ett 2026-02-05T08:54:24+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/sobi-publicerar-delarsrapport-fjarde-kvartalet-och-bokslutskommunike-2023-stark-intaktsutveckling-och-tillvaxt-i-2024 2026-02-05T08:54:20+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/sobi-publicerar-delarsrapport-fjarde-kvartalet-och-bokslutskommunike-2024-starkt-avslut-pa-ett-framgangsrikt-ar 2026-02-05T08:54:18+01:00 0.5 https://www.sobi.com/en/paroxysmal-nocturnal-haemoglobinuria-pnh 2026-02-03T13:05:29+01:00 0.5 https://www.sobi.com/en/press-releases/sobis-2025-annual-revenue-and-adjusted-ebita-margin-exceed-previous-outlook-2418454 2026-01-15T18:35:46+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobis-intakter-och-justerade-ebita-marginal-helaret-2025-overstiger-tidigare-prognos-2418453 2026-01-15T18:22:27+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-forvarvar-arthrosi-therapeutics-och-starker-sin-pipeline-med-potentiell-behandling-av-gikt-2413047 2025-12-13T17:33:22+01:00 0.5 https://www.sobi.com/en/about 2025-12-09T12:45:38+01:00 0.5 https://www.sobi.com/en/remuneration 2025-12-01T13:51:08+01:00 0.5 https://www.sobi.com/en/nomination-committee 2025-11-20T15:27:12+01:00 0.5 https://www.sobi.com/en/news-releases/sobi-relocate-its-global-headquarters-stockholm-sweden 2025-11-12T10:16:10+01:00 0.5 https://www.sobi.com/en/news-releases/sobi-welcomes-lena-bjurner-chief-human-resources-officer 2025-11-12T10:16:06+01:00 0.5 https://www.sobi.com/en/news-releases/nordic-rare-disease-summit-gathers-experts-discuss-how-care-patients-rare-health-conditions-can-be-improved-stockholm-april-17-2023 2025-11-12T10:16:03+01:00 0.5 https://www.sobi.com/en/news-releases/rare-disease-day-2023-rare-our-reason 2025-11-12T10:16:00+01:00 0.5 https://www.sobi.com/en/news-releases/rare-strength-award-winners-2023 2025-11-12T10:15:57+01:00 0.5 https://www.sobi.com/en/news-releases/sobi-and-pfizer-celebrate-opening-new-production-plant-croatia 2025-11-12T10:15:52+01:00 0.5 https://www.sobi.com/en/news-releases/sobi-enters-dow-jones-sustainability-indices-djsi 2025-11-12T10:15:48+01:00 0.5 https://www.sobi.com/en/news-releases/stills-disease-rare-disorder-hard-diagnose 2025-11-12T10:15:45+01:00 0.5 https://www.sobi.com/en/news-releases/day-learn-about-fmf 2025-11-12T10:15:40+01:00 0.5 https://www.sobi.com/en/news-releases/fcs-challenges-low-fat-life 2025-11-12T10:15:37+01:00 0.5 https://www.sobi.com/en/news-releases/people-rare-blood-disorder-be-supported-new-website-offering-symptom-recognition-tools-and-resources-improve-understanding-their 2025-11-12T10:15:34+01:00 0.5 https://www.sobi.com/en/news-releases/sobi-liberate-life-bike-ride-raises-funds-and-awareness-haemophilia 2025-11-12T10:15:31+01:00 0.5 https://www.sobi.com/en/news-releases/people-haemophilia-and-female-carriers-sweden-have-higher-risk-anxiety-depression-and-pain-based-treatment-patterns 2025-11-12T10:15:23+01:00 0.5 https://www.sobi.com/en/news-releases/patient-safety-focus 2025-11-12T10:15:19+01:00 0.5 https://www.sobi.com/en/news-releases/teams-help-healthcare-heroes 2025-11-12T10:15:16+01:00 0.5 https://www.sobi.com/en/news-releases/sobi-announces-launch-hlh-registry-disease-registry-patients-hemophagocytic-lymphohistiocytosis-hlh 2025-11-12T10:15:12+01:00 0.5 https://www.sobi.com/en/news-releases/world-haemophilia-day-2022-sobis-position-statement 2025-11-12T10:15:09+01:00 0.5 https://www.sobi.com/en/news-releases/learn-more-about-hereditary-attr-amyloidosis-hattr-world-amyloidosis-day 2025-11-12T10:15:05+01:00 0.5 https://www.sobi.com/en/news-releases/safe-use-medicines-during-pregnancy 2025-11-12T10:15:02+01:00 0.5 https://www.sobi.com/en/news-releases/patient-voice-central-our-rd 2025-11-12T10:14:59+01:00 0.5 https://www.sobi.com/en/news-releases/world-haemophilia-day-2021-adapting-change 2025-11-12T10:14:54+01:00 0.5 https://www.sobi.com/en/news-releases/fda-approves-kineretr-anakinra-treatment-deficiency-il-1-receptor-antagonist-dira 2025-11-12T10:14:51+01:00 0.5 https://www.sobi.com/en/news-releases/wesstrom-swedenbio-important-sobi 2025-11-12T10:14:48+01:00 0.5 https://www.sobi.com/en/news-releases/engaging-rare-patient-voice 2025-11-12T10:14:45+01:00 0.5 https://www.sobi.com/en/news-releases/celebrating-rare-disease-day-around-world 2025-11-12T10:14:42+01:00 0.5 https://www.sobi.com/en/news-releases/3-team-win-rare-strength-awards 2025-11-12T10:14:38+01:00 0.5 https://www.sobi.com/en/press-releases/clinically-meaningful-pivotal-study-results-olezarsen-shtg-presented-late-breaker-aha-scientific-sessions-2404396 2025-11-08T15:40:27+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/kliniskt-relevanta-resultat-fran-en-pivotal-studie-av-olezarsen-i-patienter-med-shtg-presenterades-som-late-breaker-vid-aha 2025-11-08T15:40:24+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-present-new-one-year-data-pegcetacoplans-efficacy-c3g-and-primary-ic-mpgn-and-new-outcome-data-nasp-asn-kidney-week-2403429 2025-11-05T15:00:14+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-presenterar-nya-ettarsdata-om-effekten-av-pegcetacoplan-vid-c3g-och-primar-ic-mpgn-samt-nya-utfallsdata-nasp-pa-asn-kidney-week 2025-11-05T15:00:13+01:00 0.5 https://www.sobi.com/en/our-values 2025-11-04T10:57:00+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-presenterar-nya-data-om-sallsynta-inflammatoriska-tillstand-vid-acr-2025-2400076 2025-10-24T13:59:25+02:00 0.5 https://www.sobi.com/en/press-releases/sobi-showcases-new-data-across-rare-inflammatory-conditions-acr-2025-2400078 2025-10-24T13:59:13+02:00 0.5 https://www.sobi.com/en/press-releases/change-sobi-board-directors-2398510 2025-10-21T13:08:05+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/forandring-i-sobis-styrelse-2398511 2025-10-21T13:00:15+02:00 0.5 https://www.sobi.com/en/press-releases/sobi-q3-2025-report-accelerated-growth-and-portfolio-momentum-2397923 2025-10-20T11:10:54+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-publicerar-delarsrapport-tredje-kvartalet-2025-accelererad-tillvaxt-och-momentum-i-portfoljen-2397920 2025-10-20T10:14:07+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-meddelar-reviderade-helarsutsikter-och-tidigarelagger-publiceringen-av-delarsrapporten-tredje-kvartalet-2025-2397850 2025-10-19T20:30:15+02:00 0.5 https://www.sobi.com/en/press-releases/sobi-announces-revised-full-year-outlook-and-advances-publication-q3-2025-financial-report-2397851 2025-10-19T20:30:15+02:00 0.5 https://www.sobi.com/en/press-releases/tryngolzar-olezarsen-approved-european-union-familial-chylomicronemia-syndrome-fcs-2391054 2025-10-09T09:26:01+02:00 0.5 https://www.sobi.com/en/financial-reports 2025-10-09T08:40:52+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/inbjudan-sobis-delarsrapport-tredje-kvartalet-2025-2395228 2025-10-08T13:00:13+02:00 0.5 https://www.sobi.com/en/press-releases/invitation-sobis-q3-2025-report-2395229 2025-10-08T13:00:13+02:00 0.5 https://www.sobi.com/en/financial-reports/sobi-publishes-q4-2024-report-solid-ending-strong-year 2025-10-06T09:57:13+02:00 0.5 https://www.sobi.com/en/financial-reports/sobi-q3-2024-report-strong-growth-and-significant-pipeline-momentum 2025-10-06T09:48:48+02:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/sobi-publicerar-delarsrapport-tredje-kvartalet-2024-stark-tillvaxt-och-vasentliga-framsteg-i-pipeline 2025-10-06T09:47:03+02:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/delarsrapport-jan-jun-2024 2025-10-06T09:46:31+02:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/sobi-publicerar-delarsrapport-forsta-kvartalet-2024-stark-forsaljning-speglar-styrkan-i-portfoljen 2025-10-06T09:45:50+02:00 0.5 https://www.sobi.com/en/financial-reports/interim-report-q2-2024 2025-10-06T09:18:33+02:00 0.5 https://www.sobi.com/en/financial-reports/sobi-q1-2024-report-strong-sales-reflecting-strength-portfolio 2025-10-06T09:18:00+02:00 0.5 https://www.sobi.com/en/business-strategy 2025-10-03T11:03:10+02:00 0.5 https://www.sobi.com/en/press-releases/new-number-shares-and-votes-sobi-2393133 2025-09-30T08:00:29+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/andring-av-antalet-aktier-och-roster-i-sobi-2393136 2025-09-30T08:00:29+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/tryngolzar-olezarsen-godkant-familjar-kylomikronemi-fcs-i-eu-2391053 2025-09-19T08:00:12+02:00 0.5 https://www.sobi.com/en/press-releases/invitation-sobis-nasp-and-uncontrolled-gout-call-and-webcast-2389285 2025-09-10T13:00:30+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/inbjudan-till-webcast-sobis-nasp-och-okontrollerad-gikt-2389286 2025-09-10T13:00:27+02:00 0.5 https://www.sobi.com/en/press-releases/fda-accepts-biologics-license-application-sobis-nasp-patients-uncontrolled-gout-2389168 2025-09-10T08:00:22+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/fda-accepterar-ansokan-om-marknadsgodkannande-av-nasp-patienter-med-okontrollerad-gikt-2389161 2025-09-10T08:00:13+02:00 0.5 https://www.sobi.com/en/stories 2025-03-13T21:13:18+01:00 0.5 https://www.sobi.com/en/humanitarian-aid 2025-09-05T12:12:49+02:00 0.5 https://www.sobi.com/en/press-releases/new-number-shares-and-votes-sobi-2386532 2025-08-29T08:00:20+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/andring-av-antalet-aktier-och-roster-i-sobi-2386529 2025-08-29T08:00:19+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-har-genomfort-emissioner-av-c-aktier-2383253 2025-08-21T12:35:16+02:00 0.5 https://www.sobi.com/en/press-releases/sobi-has-completed-issues-class-c-shares-2383252 2025-08-21T12:35:16+02:00 0.5 https://www.sobi.com/en/haemophilia 2025-08-12T11:45:25+02:00 0.5 https://www.sobi.com/en/press-releases/tryngolzar-olezarsen-recommended-eu-approval-chmp-familial-chylomicronemia-syndrome-fcs-2378277 2025-07-25T13:15:19+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/chmp-rekommenderar-godkannande-av-tryngolzar-olezarsen-familjar-kylomikronemi-fcs-i-eu-2378278 2025-07-25T13:15:19+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-publicerar-delarsrapport-andra-kvartalet-2025-fortsatt-starkt-momentum-i-portfolj-och-pipeline-2376276 2025-07-16T09:30:14+02:00 0.5 https://www.sobi.com/en/press-releases/sobi-publishes-q2-2025-report-continued-strong-portfolio-and-pipeline-momentum-2376275 2025-07-16T09:12:17+02:00 0.5 https://www.sobi.com/en/press-releases/board-directors-sobi-exercises-authorisation-repurchase-shares-purpose-securing-companys-commitments-under-incentive-programmes-0 2025-07-15T19:15:27+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobis-styrelse-utnyttjar-aterkopsbemyndigande-sakerstallande-av-bolagets-ataganden-enligt-incitamentsprogram-2376189 2025-07-15T19:15:27+02:00 0.5 https://www.sobi.com/en/ir-contacts 2025-07-11T10:56:47+02:00 0.5 https://www.sobi.com/en/executive-committee 2025-07-10T14:09:52+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/inbjudan-sobis-delarsrapport-andra-kvartalet-2025-2354869 2025-07-02T12:00:22+02:00 0.5 https://www.sobi.com/en/press-releases/invitation-sobis-q2-report-2354871 2025-07-02T12:00:22+02:00 0.5 https://www.sobi.com/en/press-releases/sobi-amend-existing-agreement-apellis-ex-us-royalties-aspavelir-systemic-pegcetacoplan-2349081 2025-07-01T13:50:43+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-uppdaterar-avtalet-med-apellis-om-royalty-pa-aspavelir-systemisk-pegcetacoplan-utanfor-usa-2349084 2025-07-01T13:45:10+02:00 0.5 https://www.sobi.com/en/press-releases/fda-approves-gamifantr-emapalumab-lzsg-first-ever-treatment-adults-and-children-macrophage-activation-syndrome-stills-disease-2342991 2025-06-28T00:55:20+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/fda-godkanner-gamifantr-emapalumab-lzsg-som-den-forsta-behandlingen-vuxna-och-barn-med-makrofagaktiverande-syndrom-vid-stills 2025-06-28T00:55:17+02:00 0.5 https://www.sobi.com/en/compliance 2024-10-10T08:20:01+02:00 0.5 https://www.sobi.com/en/responsible-sourcing 2025-06-24T10:55:04+02:00 0.5 https://www.sobi.com/en/clinical-studies-and-data-privacy 2025-06-24T10:53:04+02:00 0.5 https://www.sobi.com/en/sustainability-governance 2023-11-22T09:31:23+01:00 0.5 https://www.sobi.com/en/articles-association 2025-06-24T16:39:50+02:00 0.5 https://www.sobi.com/en/rights-issue-2023 2025-06-24T11:26:19+02:00 0.5 https://www.sobi.com/en/act-responsibly 2025-06-24T11:25:13+02:00 0.5 https://www.sobi.com/en/auditors 2025-06-24T10:59:55+02:00 0.5 https://www.sobi.com/en/patient-centricity 2025-06-24T11:21:45+02:00 0.5 https://www.sobi.com/en/ownership 2025-06-24T11:15:35+02:00 0.5 https://www.sobi.com/en/subscribe 2025-06-10T16:59:06+02:00 0.5 https://www.sobi.com/en/careers 2024-10-16T12:16:39+02:00 0.5 https://www.sobi.com/en/image-gallery 2025-05-16T14:57:47+02:00 0.5 https://www.sobi.com/en/financial-calendar 2025-03-04T14:42:04+01:00 0.5 https://www.sobi.com/en/share-information 2024-10-09T15:55:59+02:00 0.5 https://www.sobi.com/en/historical-share-price-look 2024-08-16T16:47:39+02:00 0.5 https://www.sobi.com/en/trade-association-memberships 2024-03-25T16:19:49+01:00 0.5 https://www.sobi.com/en/open-positions 2024-01-11T15:53:20+01:00 0.5 https://www.sobi.com/en/history 2024-10-11T10:18:19+02:00 0.5 https://www.sobi.com/en/partnership 2024-10-11T10:16:59+02:00 0.5 https://www.sobi.com/en/general-meetings 2024-10-09T20:14:20+02:00 0.5 https://www.sobi.com/en/all-trading-venues 2024-10-09T15:56:39+02:00 0.5 https://www.sobi.com/en/transparency 2024-08-16T11:53:03+02:00 0.5 https://www.sobi.com/en/press-releases/sobi-will-showcase-extensive-research-and-clinical-outcomes-isth-2025-2340954 2025-06-20T08:00:24+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-visar-omfattande-forskning-och-kliniska-resultat-vid-isth-2025-2340955 2025-06-20T08:00:24+02:00 0.5 https://www.sobi.com/en/news-releases/encouraging-sustainable-commuting-france 2025-06-18T08:38:11+02:00 0.5 https://www.sobi.com/en/press-releases/sobi-share-new-clinical-data-across-multiple-hematologic-diseases-eha-2025-2338975 2025-06-12T10:00:12+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-presenterar-nya-kliniska-data-om-ett-flertal-hematologiska-sjukdomar-vid-eha-2025-2338976 2025-06-12T10:00:12+02:00 0.5 https://www.sobi.com/en/news-releases/advancing-care-rare-kidney-diseases-reflections-era-congress 2025-06-12T08:30:06+02:00 0.5 https://www.sobi.com/en/c3g-and-primary-ic-mpgn 2025-06-10T10:58:58+02:00 0.5 https://www.sobi.com/en/news-releases/sobis-climate-targets-approved-sbti 2025-06-10T10:46:45+02:00 0.5 https://www.sobi.com/en/news-releases/sobi-recognised-sp-global-sustainability-yearbook-2025 2025-06-09T15:31:49+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-och-apellis-aspavelirempavelir-visar-ett-ars-varaktig-effekt-i-fas-3-studie-vid-sallsynta-njursjukdomar-2336847 2025-06-06T15:15:21+02:00 0.5 https://www.sobi.com/en/press-releases/sobi-and-apellis-aspavelirempavelir-demonstrates-sustained-one-year-efficacy-phase-3-study-rare-kidney-diseases-2336846 2025-06-06T15:15:21+02:00 0.5 https://www.sobi.com/en/press-releases/sobi-showcases-breadth-data-c3gprimary-ic-mpgn-era-2025-2336179 2025-06-04T12:12:52+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-presenterar-omfattande-data-inom-c3g-och-primar-ic-mpgn-vid-era-2025-2336175 2025-06-04T11:56:06+02:00 0.5 https://www.sobi.com/en/press-releases/invitation-sobis-aspavelir-52-week-phase-3-valiant-data-nephrology-2335865 2025-06-03T11:00:26+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/inbjudan-sobis-aspavelir-52-veckors-data-fran-fas-3-studien-valiant-inom-nefrologi-2335864 2025-06-03T11:00:26+02:00 0.5 https://www.sobi.com/en/press-releases/us-fda-grants-priority-review-sobis-supplemental-biologics-licence-application-sbla-gamifant-r-emapalumab-lzsg-2304690 2025-06-02T16:34:26+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-meddelar-att-fda-accepterat-att-paborja-granskning-av-tillaggsansokan-gamifantr-emapalumab-lzsg-2304689 2025-06-02T16:34:26+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-tillkannager-ett-nytt-forskningssamarbete-kring-utveckling-av-gamifantr-emapalumab-vid-sepsis-som-presenteras-vid-isicem 2025-06-02T16:26:41+02:00 0.5 https://www.sobi.com/en/press-releases/sobi-announces-new-research-collaboration-development-gamifantr-emapalumab-sepsis-which-be-presented-isicem-congress-2310246 2025-06-02T16:26:41+02:00 0.5 https://www.sobi.com/en/press-releases/sobi-share-new-clinical-data-and-research-eular-2025-2334491 2025-05-28T09:52:51+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-presenterar-nya-kliniska-data-och-forskning-vid-eular-2025-2334493 2025-05-28T09:52:51+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/kommunike-fran-sobis-arsstamma-2328480 2025-05-08T11:30:14+02:00 0.5 https://www.sobi.com/en/press-releases/bulletin-sobis-annual-general-meeting-agm-2328479 2025-05-08T11:30:14+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-publicerar-delarsrapport-forsta-kvartalet-2025-portfoljen-fortsatter-att-leverera-2324508 2025-04-29T08:31:41+02:00 0.5 https://www.sobi.com/en/press-releases/sobi-publishes-q1-2025-report-portfolio-continues-deliver-2324518 2025-04-29T08:25:30+02:00 0.5 https://www.sobi.com/en/news-releases/transforming-lives-through-collaboration-renewed-commitment-global-haemophilia-care 2025-04-25T07:47:20+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-och-sanofi-fornyar-partnerskap-med-world-federation-hemophilias-humanitara-bistandsprogram-2323075 2025-04-25T06:00:23+02:00 0.5 https://www.sobi.com/en/press-releases/sobi-and-sanofis-foundation-s-extend-partnership-world-federation-hemophilia-humanitarian-aid-program-2323074 2025-04-25T06:00:20+02:00 0.5 https://www.sobi.com/en/press-releases/sobi-presents-clinical-data-wfh-2025-comprehensive-care-summit-2321792 2025-04-23T17:33:44+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-presentarar-kliniska-data-vid-wfh-2025-comprenhensive-care-summit-2321789 2025-04-23T07:00:19+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/inbjudan-sobis-delarsrapport-forsta-kvartalet-2025-2320370 2025-04-15T12:00:24+02:00 0.5 https://www.sobi.com/en/press-releases/invitation-sobis-q1-report-2320373 2025-04-15T12:00:24+02:00 0.5 https://www.sobi.com/en/caring-employees 2025-04-01T10:16:00+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/kallelse-till-arsstamma-i-swedish-orphan-biovitrum-ab-publ-2315520 2025-04-01T08:00:30+02:00 0.5 https://www.sobi.com/en/press-releases/notice-annual-general-meeting-swedish-orphan-biovitrum-ab-publ-2315521 2025-04-01T08:00:30+02:00 0.5 https://www.sobi.com/en/press-releases/sobi-publishes-annual-and-sustainability-report-2024-2315148 2025-03-31T12:07:50+02:00 0.5 https://www.sobi.com/en/financial-reports/sobi-publishes-annual-and-sustainability-report-2024 2025-03-31T11:49:39+02:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/sobi-publicerar-sin-ars-och-hallbarhetsredovisning-2024 2025-03-31T11:49:05+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-publicerar-sin-ars-och-hallbarhetsredovisning-2024-2315150 2025-03-31T11:48:18+02:00 0.5 https://www.sobi.com/en/news-releases/sobi-expands-partnership-ionis-pharmaceuticals-include-olezarsen-commercialisation-outside-us 2025-03-26T12:04:00+01:00 0.5 https://www.sobi.com/en/news-releases/more-you-can-imagine-rare-disease-day-2025 2025-02-26T11:17:13+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/ema-validerar-ansokan-om-utvidgad-indikation-aspavelir-vid-behandling-av-c3g-och-primar-ic-mpgn-2302720 2025-02-20T08:00:25+01:00 0.5 https://www.sobi.com/en/press-releases/ema-validates-indication-extension-application-aspavelir-treatment-c3g-and-primary-ic-mpgn-2302717 2025-02-20T08:00:24+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-publishes-q4-2024-report-solid-ending-strong-year-2297727 2025-02-05T08:59:21+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-publicerar-delarsrapport-fjarde-kvartalet-och-bokslutskommunike-2024-starkt-avslut-pa-ett-framgangsrikt-ar-2297726 2025-02-05T08:59:14+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/inbjudan-sobis-delarsrapport-fjarde-kvartalet-och-bokslutskommunike-2024-2294201 2025-02-04T10:29:00+01:00 0.5 https://www.sobi.com/en/unite4rare/connect 2025-01-29T15:26:34+01:00 0.5 https://www.sobi.com/en/unite4rare/nurture 2025-01-29T15:34:25+01:00 0.5 https://www.sobi.com/en/unite4rare/collaborate 2025-01-29T15:33:20+01:00 0.5 https://www.sobi.com/en/unite4rare/innovate 2025-01-29T15:26:51+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-presenterar-sin-senaste-hemofiliforskning-pa-eahad-2025-2295505 2025-01-29T08:23:52+01:00 0.5 https://www.sobi.com/en/press-releases/sobis-latest-haemophilia-research-be-presented-eahad-2025-2295512 2025-01-29T08:20:44+01:00 0.5 https://www.sobi.com/en/press-releases/invitation-sobis-q4-and-fy-2024-report-2294202 2025-01-21T13:00:19+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobis-intakter-helaret-2024-hogre-tidigare-uppskattningar-2292209 2025-01-10T18:00:27+01:00 0.5 https://www.sobi.com/en/press-releases/sobis-full-year-2024-revenue-higher-previous-estimate-2292208 2025-01-10T18:00:24+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/kommunike-fran-sobis-extra-bolagsstamma-2287024 2024-12-11T09:30:23+01:00 0.5 https://www.sobi.com/en/press-releases/bulletin-sobis-extraordinary-general-meeting-egm-2287025 2024-12-11T09:30:23+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-visar-sin-styrka-inom-hematologi-pa-ash-2024-2285058 2024-12-03T08:00:18+01:00 0.5 https://www.sobi.com/en/press-releases/sobis-strength-haematology-be-showcased-ash-2024-2285050 2024-12-03T08:00:17+01:00 0.5 https://www.sobi.com/en/news-releases/introducing-unite4rare 2024-12-03T06:49:42+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/kallelse-till-extra-bolagsstamma-i-swedish-orphan-biovitrum-ab-publ-2278823 2024-11-11T08:00:27+01:00 0.5 https://www.sobi.com/en/press-releases/notice-extraordinary-general-meeting-swedish-orphan-biovitrum-ab-publ-2278821 2024-11-11T08:00:27+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/david-meek-foreslas-som-ny-styrelseordforande-i-sobi-2277001 2024-11-04T21:00:27+01:00 0.5 https://www.sobi.com/en/press-releases/david-meek-proposed-new-chair-board-directors-sobi-2277002 2024-11-04T21:00:27+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/nya-data-emapalumab-vid-behandling-av-makrofagaktiverande-syndrom-presenteras-pa-acr-konferensen-2275521 2024-10-30T08:00:27+01:00 0.5 https://www.sobi.com/en/press-releases/new-data-emapalumab-treatment-macrophage-activation-syndrome-be-presented-acr-conference-2275523 2024-10-30T08:00:27+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/resultat-fran-den-pivotala-studien-valiant-presenterade-vid-kidney-week-visar-behandlingseffekt-med-pegcetacoplan-hos-patienter-med 2024-10-26T20:00:29+02:00 0.5 https://www.sobi.com/en/press-releases/pivotal-valiant-results-presented-kidney-week-show-pegcetacoplan-treatment-effect-patients-c3g-primary-ic-mpgn-2274618 2024-10-26T20:00:26+02:00 0.5 https://www.sobi.com/en/press-releases/invitation-sobis-aspavelir-and-phase-3-valiant-data-nephrology-call-2274476 2024-10-25T13:00:22+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/inbjudan-sobis-telefonkonferens-om-aspavelir-och-fas-3-studien-valiant-inom-nefrologi-2274471 2024-10-25T13:00:21+02:00 0.5 https://www.sobi.com/en/press-releases/sobi-q3-2024-report-strong-growth-and-significant-pipeline-momentum-2273758 2024-10-24T08:00:44+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-publicerar-delarsrapport-tredje-kvartalet-2024-stark-tillvaxt-och-vasentliga-framsteg-i-pipeline-2273744 2024-10-24T08:00:43+02:00 0.5 https://www.sobi.com/en/financial-data 2024-10-09T15:53:19+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/inbjudan-sobis-delarsrapport-tredje-kvartalet-2024-2269899 2024-10-09T13:00:13+02:00 0.5 https://www.sobi.com/en/press-releases/invitation-sobis-q3-2024-report-2269900 2024-10-09T13:00:13+02:00 0.5 https://www.sobi.com/en/news-releases/sobi-moves-new-global-headquarters-stockholm 2024-09-30T08:51:07+02:00 0.5 https://www.sobi.com/en/press-releases/new-number-shares-and-votes-sobi-2267497 2024-09-30T08:00:22+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/andring-av-antalet-aktier-och-roster-sobi-2267495 2024-09-30T08:00:20+02:00 0.5 https://www.sobi.com/en/press-releases/sobir-and-enable-injections-announce-agreement-develop-and-distribute-aspavelir-combination-enfuser-sobi-territories-2263760 2024-09-12T14:00:23+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobir-och-enable-injections-tillkannager-avtal-om-att-utveckla-och-distribuera-aspavelir-i-kombination-med-enfuser-pa-sobis 2024-09-12T14:00:23+02:00 0.5 https://www.sobi.com/en/press-releases/invitation-sobis-q4-and-fy-2023-report-2193976 2024-09-09T17:36:54+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/inbjudan-sobis-delarsrapport-fjarde-kvartalet-och-bokslutskommunike-2023-2193979 2024-09-09T17:36:54+02:00 0.5 https://www.sobi.com/en/press-releases/sobi-publishes-q4-2023-report-strong-revenue-performance-and-growth-2024-2201620 2024-09-09T17:36:54+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-publicerar-delarsrapport-fjarde-kvartalet-och-bokslutskommunike-2023-stark-intaktsutveckling-och-tillvaxt-i-2024-2201625 2024-09-09T17:36:54+02:00 0.5 https://www.sobi.com/en/press-releases/sobi-publishes-annual-and-sustainability-report-2023-2217790 2024-09-09T17:36:54+02:00 0.5 https://www.sobi.com/en/financial-reports/sobi-publishes-annual-and-sustainability-report-2023 2024-09-09T17:36:54+02:00 0.5 https://www.sobi.com/en/press-releases/sobi-has-completed-issues-class-c-shares-2260703 2024-09-09T17:36:54+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-har-genomfort-emissioner-av-c-aktier-2260704 2024-09-09T17:36:54+02:00 0.5 https://www.sobi.com/en/press-releases/sobi-and-apellis-announce-positive-topline-results-phase-3-valiant-study-pegcetacoplan-c3g-and-primary-ic-mpgn-2255513 2024-08-08T13:00:11+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-och-apellis-meddelar-positiva-topline-resultat-fran-fas-3-studien-valiant-med-pegcetacoplan-vid-c3g-och-primar-ic-mpgn-2255514 2024-08-08T13:00:11+02:00 0.5 https://www.sobi.com/en/news-releases/sobi-and-save-one-life-foundation-support-people-haemophilia-scale-new-heights 2024-07-18T10:17:00+02:00 0.5 https://www.sobi.com/en/press-releases/nejm-publishes-altuvoctr-phase-3-xtend-kids-results-highlighting-treatment-potential-children-severe-haemophilia-2252089 2024-07-18T08:00:32+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/nejm-publicerar-resultat-fran-fas-3-studien-xtend-kids-med-altuvoctr-som-visar-behandlingspotentialen-barn-med-svar-hemofili-2252086 2024-07-18T08:00:32+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-publicerar-delarsrapport-andra-kvartalet-2024-stark-leverans-driven-av-robust-utveckling-i-portfoljen-2251556 2024-07-16T08:36:13+02:00 0.5 https://www.sobi.com/en/press-releases/sobi-q2-2024-report-strong-delivery-driven-robust-portfolio-performance-2251555 2024-07-16T08:29:22+02:00 0.5 https://www.sobi.com/en/press-releases/board-directors-sobi-exercises-authorisation-repurchase-shares-purpose-securing-companys-commitments-under-incentive-programmes 2024-07-15T19:15:17+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobis-styrelse-utnyttjar-aterkopsbemyndigande-sakerstallande-av-bolagets-ataganden-enligt-incitamentsprogram-2251474 2024-07-15T19:15:17+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/inbjudan-sobis-delarsrapport-andra-kvartalet-2024-2249089 2024-07-03T14:00:25+02:00 0.5 https://www.sobi.com/en/press-releases/invitation-sobis-q2-2024-report-2249090 2024-07-03T14:00:25+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-paborjar-stegvis-ansokan-om-marknadsgodkannande-hos-fda-sel-212-vid-potentiell-behandling-av-kronisk-refraktar-gikt-2248618 2024-07-02T08:00:25+02:00 0.5 https://www.sobi.com/en/press-releases/sobi-initiates-rolling-biologics-license-application-fda-sel-212-potential-treatment-chronic-refractory-gout-2248612 2024-07-02T08:00:24+02:00 0.5 https://www.sobi.com/en/news-releases/world-haemophilia-day-2024-sobis-position-statement 2024-06-19T14:02:26+02:00 0.5 https://www.sobi.com/en/press-releases/european-commission-grants-sobir-marketing-authorisation-altuvocttm-treatment-haemophilia-2245139 2024-06-19T08:00:29+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/eu-kommissionen-beviljar-sobir-marknadsgodkannande-altuvocttm-behandling-av-hemofili-2245135 2024-06-19T08:00:29+02:00 0.5 https://www.sobi.com/en/press-releases/sobi-present-new-haemophilia-data-isth-2024-2244342 2024-06-17T08:00:25+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-presenterar-nya-data-om-hemofili-vid-isth-2024-2244338 2024-06-17T08:00:25+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-presenterar-nya-data-fran-sin-hematologiportfolj-pa-eha-kongressen-2024-2242263 2024-06-10T12:15:19+02:00 0.5 https://www.sobi.com/en/press-releases/sobi-present-new-data-across-its-haematology-portfolio-2024-eha-congress-2242264 2024-06-10T12:15:19+02:00 0.5 https://www.sobi.com/en/code-of-conduct 2024-05-27T16:40:31+02:00 0.5 https://www.sobi.com/en/press-releases/positive-data-phase-2-noble-study-pegcetacoplan-presented-late-breaker-era-congress-2237892 2024-05-24T16:05:25+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/positiva-data-fran-fas-2-studien-noble-med-pegcetacoplan-presenterade-som-late-breaker-vid-era-kongressen-2237891 2024-05-24T16:05:25+02:00 0.5 https://www.sobi.com/en/press-releases/bulletin-sobis-annual-general-meeting-agm-2232970 2024-05-14T16:45:18+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/kommunike-fran-sobis-arsstamma-2232972 2024-05-14T16:45:18+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-har-emitterat-seniora-obligationer-om-3-miljarder-kronor-2230700 2024-05-08T11:24:53+02:00 0.5 https://www.sobi.com/en/press-releases/sobi-has-completed-sek-3-billion-senior-bond-issue-2230701 2024-05-08T11:24:53+02:00 0.5 https://www.sobi.com/en/press-releases/aspavelir-pegcetacoplan-approved-europe-use-among-treatment-naive-adult-patients-pnh-2230638 2024-05-08T10:15:18+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/aspavelir-pegcetacoplan-godkant-i-europa-anvandning-hos-behandlingsnaiva-vuxna-patienter-med-pnh-2230639 2024-05-08T10:15:18+02:00 0.5 https://www.sobi.com/en/press-releases/sobir-receives-positive-chmp-opinion-recommending-approval-efanesoctocog-alfa-once-weekly-treatment-haemophilia-2226433 2024-04-26T13:35:23+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobir-far-positivt-chmp-utlatande-som-rekommenderar-godkannande-av-efanesoctocog-alfa-behandling-en-gang-i-veckan-av-hemofili 2024-04-26T13:35:23+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-etablerar-mtn-program-med-en-ram-om-10-miljarder-kronor-offentliggor-grundprospekt-2226314 2024-04-26T10:30:18+02:00 0.5 https://www.sobi.com/en/press-releases/sobi-establishes-mtn-programme-framework-amount-sek-10-billion-publishes-base-prospectus-2226315 2024-04-26T10:30:18+02:00 0.5 https://www.sobi.com/en/press-releases/sobi-q1-2024-report-strong-sales-reflecting-strength-portfolio-2225429 2024-04-25T16:09:35+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-publicerar-delarsrapport-forsta-kvartalet-2024-stark-forsaljning-speglar-styrkan-i-portfoljen-2225434 2024-04-25T16:08:34+02:00 0.5 https://www.sobi.com/en/haemophilia-10 2024-04-25T11:48:49+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/inbjudan-sobis-delarsrapport-forsta-kvartalet-2024-2221487 2024-04-15T10:00:18+02:00 0.5 https://www.sobi.com/en/press-releases/invitation-sobis-q1-2024-report-2221491 2024-04-15T10:00:18+02:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/ars-och-hallbarhetsredovisningen-2021 2024-04-10T10:08:46+02:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/sobir-publicerar-sin-ars-och-hallbarhetsredovisning-2022 2024-04-10T10:07:22+02:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/sobi-publicerar-sin-ars-och-hallbarhetsredovisning-2023 2024-04-10T10:06:28+02:00 0.5 https://www.sobi.com/en/press-releases/sobir-publishes-annual-and-sustainability-report-2022-2110115 2024-04-08T15:43:25+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobir-publicerar-sin-ars-och-hallbarhetsredovisning-2022-2110117 2024-04-08T15:43:16+02:00 0.5 https://www.sobi.com/en/press-releases/notice-annual-general-meeting-swedish-orphan-biovitrum-ab-publ-2218495 2024-04-04T08:00:58+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/kallelse-till-arsstamma-i-swedish-orphan-biovitrum-ab-publ-2218485 2024-04-04T08:00:43+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-publicerar-sin-ars-och-hallbarhetsredovisning-2023-2217791 2024-04-02T11:05:09+02:00 0.5 https://www.sobi.com/en/press-releases/sobi-announces-positive-results-phase-3-study-dopteletr-treatment-children-and-adolescents-itp-2215547 2024-03-25T08:00:34+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-meddelar-positiva-resultat-fran-fas-3-studie-med-dopteletr-behandling-av-barn-och-ungdomar-med-itp-2215548 2024-03-25T08:00:34+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/arsredovisning-2009-2215258 2024-03-22T11:50:47+01:00 0.5 https://www.sobi.com/en/press-releases/annual-report-2009-2215257 2024-03-22T11:37:00+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/bokslutskommunike-2009-2215285 2024-03-22T11:33:31+01:00 0.5 https://www.sobi.com/en/press-releases/report-q4-and-full-year-2009-2215290 2024-03-22T11:28:52+01:00 0.5 https://www.sobi.com/en/financial-reports/report-q4-and-full-year-2009 2024-03-22T11:26:47+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/bokslutskommunike-2009 2024-03-22T11:18:16+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/arsredovisning-2009 2024-03-22T10:58:56+01:00 0.5 https://www.sobi.com/en/financial-reports/annual-report-2009-0 2024-03-22T10:53:04+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-och-handok-bildar-joint-venture-verksamhet-inom-sallsynta-sjukdomar-i-sydkorea-2202804 2024-02-13T07:00:19+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-and-handok-establish-joint-venture-rare-disease-business-south-korea-2202799 2024-02-13T07:00:14+01:00 0.5 https://www.sobi.com/en/financial-reports/sobi-publishes-q4-2023-report-strong-revenue-performance-and-growth-2024 2024-02-08T13:11:49+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-present-new-data-eahad-2024-2196720 2024-01-31T07:00:21+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-presenterar-nya-data-pa-eahad-2024-2196718 2024-01-31T07:00:17+01:00 0.5 https://www.sobi.com/en/press-releases/sobis-chairman-board-resigns-due-health-reasons-2190146 2024-01-05T08:00:22+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobis-styrelseordforande-lamnar-sitt-uppdrag-pa-grund-av-halsoskal-2190147 2024-01-05T08:00:22+01:00 0.5 https://www.sobi.com/en/news-releases/sobi-once-again-dow-jones-sustainability-indices 2023-12-18T16:11:23+01:00 0.5 https://www.sobi.com/en/press-releases/change-number-shares-and-votes-swedish-orphan-biovitrum-ab-publ-2180457 2023-11-30T08:00:38+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/andring-av-antalet-aktier-och-roster-i-swedish-orphan-biovitrum-ab-publ-2180454 2023-11-30T08:00:38+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/paminnelse-sobi-kol-presentation-forbattringar-av-vardstandarden-inom-hemofili-2158179 2023-11-23T14:20:32+01:00 0.5 https://www.sobi.com/en/press-releases/reminder-sobi-kol-investor-event-advancing-standard-care-haemophilia-2158180 2023-11-23T14:19:30+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-present-new-data-ash-2023-annual-meeting-2177591 2023-11-20T08:00:29+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-presenterar-nya-data-pa-ash-kongressen-2023-2177579 2023-11-20T08:00:24+01:00 0.5 https://www.sobi.com/sv/news-releases/fcs-awareness-day-kannedom-och-kunskap-kan-radda-liv 2023-11-03T08:58:32+01:00 0.5 https://www.sobi.com/en/news-releases/fcs-awareness-day-attention-and-knowledge-can-save-lives 2023-11-03T08:52:10+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-has-completed-issuances-series-c-shares-2172392 2023-11-01T18:00:16+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-har-genomfort-en-emission-av-c-aktier-2172394 2023-11-01T18:00:16+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-issues-series-c-shares-fulfil-its-obligations-under-outstanding-incentive-programmes-2171937 2023-10-31T18:00:21+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-emitterar-c-aktier-att-fullgora-sina-ataganden-under-utestaende-incitamentsprogram-2171940 2023-10-31T18:00:21+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/sobi-publicerar-delarsrapport-tredje-kvartalet-2023-stark-forsaljning-och-stabil-leverans 2023-10-30T12:40:41+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/delarsrapport-jan-juni-2023 2023-10-30T12:39:19+01:00 0.5 https://www.sobi.com/en/financial-reports/sobi-publishes-q3-2023-report-strong-revenue-and-solid-performance 2023-10-30T12:32:01+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-publishes-q3-2023-report-strong-revenue-and-solid-performance-2171157 2023-10-30T08:00:21+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-publicerar-delarsrapport-tredje-kvartalet-2023-stark-forsaljning-och-stabil-leverans-2171158 2023-10-30T08:00:21+01:00 0.5 https://www.sobi.com/en/press-releases/reminder-invitation-sobis-q3-2023-report-2170848 2023-10-27T11:00:15+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/paminnelse-inbjudan-sobis-delarsrapport-tredje-kvartalet-2023-2170854 2023-10-27T11:00:15+02:00 0.5 https://www.sobi.com/en/press-releases/invitation-sobis-q3-2023-report-2165918 2023-10-18T15:00:18+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/inbjudan-sobis-delarsrapport-tredje-kvartalet-2023-2165917 2023-10-18T15:00:14+02:00 0.5 https://www.sobi.com/en/press-releases/sobi-announces-positive-phase-2-noble-results-pegcetacoplan-post-transplant-recurrence-primary-ic-mpgn-and-c3g-2165570 2023-10-17T13:15:15+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-meddelar-positiva-resultat-fran-fas-2-studien-noble-med-pegcetacoplan-vid-aterfall-i-primar-ic-mpgn-och-c3g-efter 2023-10-17T13:15:15+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-utser-lydia-abad-franch-till-head-rd-och-chief-medical-officer-2162908 2023-10-05T08:00:19+02:00 0.5 https://www.sobi.com/en/press-releases/sobi-appoints-lydia-abad-franch-head-rd-and-chief-medical-officer-2162906 2023-10-05T08:00:18+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/andring-av-antalet-aktier-och-roster-i-swedish-orphan-biovitrum-ab-publ-2161294 2023-09-29T08:00:19+02:00 0.5 https://www.sobi.com/en/press-releases/change-number-shares-and-votes-swedish-orphan-biovitrum-ab-publ-2161295 2023-09-29T08:00:19+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-offentliggor-slutligt-utfall-i-foretradesemissionen-2158854 2023-09-19T18:31:22+02:00 0.5 https://www.sobi.com/en/press-releases/sobi-publishes-final-outcome-rights-issue-2158855 2023-09-19T18:30:50+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-offentliggor-preliminart-utfall-i-foretradesemissionen-2158591 2023-09-18T18:01:37+02:00 0.5 https://www.sobi.com/en/press-releases/sobi-publishes-preliminary-outcome-rights-issue-2158593 2023-09-18T18:00:57+02:00 0.5 https://www.sobi.com/en/eng-content-page-disclaimer-test 2023-07-17T09:57:18+02:00 0.5 https://www.sobi.com/en/press-releases/sobi-kol-investor-event-advancing-standard-care-haemophilia-2156702 2023-09-08T13:30:21+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-kol-presentation-forbattringar-av-vardstandarden-inom-hemofili-2156703 2023-09-08T13:30:17+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-offentliggor-prospekt-avseende-foretradesemissionen-2153434 2023-08-28T12:01:23+02:00 0.5 https://www.sobi.com/en/press-releases/sobi-publishes-prospectus-regarding-rights-issue-2153437 2023-08-28T12:00:45+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-beslutar-om-en-foretradesemission-om-cirka-6-024-miljoner-sek-2151880 2023-08-22T20:31:24+02:00 0.5 https://www.sobi.com/en/press-releases/sobi-resolves-rights-issue-approximately-sek-6024-million-2151881 2023-08-22T20:30:51+02:00 0.5 https://www.sobi.com/en/press-releases/bulletin-swedish-orphan-biovitrum-sobis-extraordinary-general-meeting-egm-2149959 2023-08-15T13:14:52+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/kommunike-fran-swedish-orphan-biovitrums-sobi-extra-bolagsstamma-2149958 2023-08-15T13:14:52+02:00 0.5 https://www.sobi.com/en/news-releases/lotis-9-study-update 2023-07-21T11:03:52+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-kol-presentation-av-vonjor-investerare-2144691 2023-07-19T15:20:40+02:00 0.5 https://www.sobi.com/en/press-releases/sobi-kol-investor-event-journey-vonjor-2144690 2023-07-19T15:20:26+02:00 0.5 https://www.sobi.com/en/financial-reports/interim-report-q2-2023 2023-07-18T11:33:13+02:00 0.5 https://www.sobi.com/en/press-releases/sobi-publishes-q2-2023-report-growth-and-pipeline-expansion-2145101 2023-07-18T09:47:46+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-publicerar-delarsrapport-andra-kvartalet-2023-tillvaxt-och-utokad-pipeline-2145100 2023-07-18T08:50:38+02:00 0.5 https://www.sobi.com/en/press-releases/notice-extraordinary-general-meeting-swedish-orphan-biovitrum-ab-publ-2145103 2023-07-18T08:15:23+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/kallelse-till-extra-bolagsstamma-i-swedish-orphan-biovitrum-ab-publ-2145104 2023-07-18T08:15:23+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-avser-att-genomfora-en-foretradesemission-om-cirka-6-000-miljoner-sek-och-kallar-till-extra-bolagsstamma-att-hallas-den-15 2023-07-18T08:06:06+02:00 0.5 https://www.sobi.com/en/press-releases/sobi-intends-carry-out-rights-issue-approximately-sek-6000-million-and-calls-extraordinary-general-meeting-be-held-15-august-2023 2023-07-18T08:04:26+02:00 0.5 https://www.sobi.com/en/press-releases/sobi-present-new-data-ash-2022-annual-meeting-2068037 2023-07-18T07:39:13+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/inbjudan-sobis-delarsrapport-andra-kvartalet-2023-2143731 2023-07-11T10:30:18+02:00 0.5 https://www.sobi.com/en/press-releases/invitation-sobis-q2-2023-report-2143732 2023-07-11T10:30:18+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-presenterar-nya-data-pa-ash-arliga-kongress-2022-2068038 2023-07-07T15:00:59+02:00 0.5 https://www.sobi.com/en/press-releases/new-number-shares-and-votes-swedish-orphan-biovitrum-ab-publ-2141517 2023-06-30T14:01:22+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/andring-av-antalet-aktier-och-roster-i-swedish-orphan-biovitrum-ab-publ-2141516 2023-06-30T14:01:17+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-har-slutfort-forvarvet-av-cti-biopharma-corp-2139735 2023-06-26T15:00:09+02:00 0.5 https://www.sobi.com/en/press-releases/sobi-completes-acquisition-cti-biopharma-corp-2139734 2023-06-26T15:00:09+02:00 0.5 https://www.sobi.com/en/press-releases/late-breaking-efanesoctocog-alfa-data-presented-isth-demonstrates-highly-effective-bleed-protection-children-severe-haemophilia-once 2023-06-25T16:45:20+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/nya-data-om-efanesoctocog-alfa-presenterade-vid-isth-visar-ett-mycket-effektivt-skydd-mot-blodningar-hos-barn-med-svar-hemofili-vid 2023-06-25T16:45:20+02:00 0.5 https://www.sobi.com/en/press-releases/sobi-successfully-completes-tender-offer-all-outstanding-shares-common-stock-cti-biopharma-corp-2139481 2023-06-24T06:50:18+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-har-framgangsrikt-slutfort-uppkopserbjudandet-avseende-samtliga-utestaende-stamaktier-i-cti-biopharma-corp-2139482 2023-06-24T06:50:15+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobis-styrelse-utnyttjar-aterkopsbemyndigande-sakerstallande-av-bolagets-ataganden-enligt-incitamentsprogram-2138093 2023-06-20T14:28:34+02:00 0.5 https://www.sobi.com/en/press-releases/board-directors-sobi-exercises-authorisation-repurchase-shares-purpose-securing-companys-commitments-under-incentive-programme-2138058 2023-06-20T13:00:19+02:00 0.5 https://www.sobi.com/en/press-releases/changes-sobis-management-2137694 2023-06-19T14:45:13+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/ledningsforandring-i-sobi-2137696 2023-06-19T14:45:13+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-presenterar-nya-data-vid-isth-2023-2136208 2023-06-14T10:00:25+02:00 0.5 https://www.sobi.com/en/press-releases/sobi-present-new-data-isth-2023-2136209 2023-06-14T10:00:25+02:00 0.5 https://www.sobi.com/en/press-releases/sobi-present-new-data-2023-eha-congress-2132353 2023-06-02T15:27:20+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-presenterar-nya-data-pa-eha-kongressen-2023-2132354 2023-06-02T09:00:23+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-inleder-ett-uppkopserbjudande-avseende-samtliga-utestaende-stamaktier-i-cti-biopharma-corp-2130066 2023-05-25T13:49:53+02:00 0.5 https://www.sobi.com/en/press-releases/sobi-commences-tender-offer-all-outstanding-shares-common-stock-cti-biopharma-corp-2130069 2023-05-25T13:45:31+02:00 0.5 https://www.sobi.com/en/press-releases/ema-validates-marketing-authorisation-application-efanesoctocog-alfa-treatment-haemophilia-2128255 2023-05-25T09:13:52+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/ema-validerar-ansokan-om-marknadsgodkannande-efanesoctocog-alfa-vid-behandling-av-hemofili-2128256 2023-05-19T07:00:14+02:00 0.5 https://www.sobi.com/en/press-releases/sobi-acquire-cti-biopharma-corp-enhancing-sobis-position-rare-haematology-2124874 2023-05-10T10:01:46+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-avser-att-forvarva-cti-biopharma-corp-starker-sobis-position-inom-sallsynt-hematologi-2124873 2023-05-10T07:00:19+02:00 0.5 https://www.sobi.com/en/press-releases/bulletin-swedish-orphan-biovitrum-sobis-annual-general-meeting-agm-2124770 2023-05-09T16:55:19+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/kommunike-fran-swedish-orphan-biovitrums-sobi-arsstamma-2124771 2023-05-09T16:55:19+02:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/sobi-publicerar-delarsrapport-forsta-kvartalet-2023-fortsatt-stabil-utveckling 2023-04-27T12:12:39+02:00 0.5 https://www.sobi.com/en/financial-reports/sobi-publishes-q1-2023-report-continued-solid-progress 2023-04-27T12:12:01+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-publicerar-delarsrapport-forsta-kvartalet-2023-fortsatt-stabil-utveckling-2119569 2023-04-27T08:06:59+02:00 0.5 https://www.sobi.com/en/press-releases/sobi-publishes-q1-2023-report-continued-solid-progress-2119551 2023-04-27T08:02:58+02:00 0.5 https://www.sobi.com/en/press-releases/invitation-sobis-q1-2023-report-2115834 2023-04-19T11:00:25+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/inbjudan-sobis-delarsrapport-forsta-kvartalet-2023-2115835 2023-04-19T11:00:25+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-renodlar-avtalet-nirsevimab-2112026 2023-04-12T11:28:56+02:00 0.5 https://www.sobi.com/en/press-releases/sobi-streamline-nirsevimab-contractual-arrangements-2112027 2023-04-12T11:28:30+02:00 0.5 https://www.sobi.com/en/financial-reports/sobir-publishes-annual-and-sustainability-report-2022 2023-04-03T08:05:55+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-publicerar-delarsrapport-forsta-kvartalet-2022-2014155 2023-03-30T14:41:02+02:00 0.5 https://www.sobi.com/en/press-releases/sobi-publishes-q1-2022-report-2014147 2023-03-30T14:38:17+02:00 0.5 https://www.sobi.com/en/press-releases/sobi-publishes-q2-2022-report-2037290 2023-03-30T14:36:02+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-publicerar-delarsrapport-andra-kvartalet-2022-2037291 2023-03-30T14:36:02+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-publicerar-delarsrapport-tredje-kvartalet-2022-2063124 2023-03-30T14:27:02+02:00 0.5 https://www.sobi.com/en/press-releases/sobi-publishes-q3-2022-report-2063134 2023-03-30T14:27:02+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/kallelse-till-arsstamma-i-swedish-orphan-biovitrum-ab-publ-2108884 2023-03-30T08:00:29+02:00 0.5 https://www.sobi.com/en/press-releases/notice-annual-general-meeting-swedish-orphan-biovitrum-ab-publ-2108881 2023-03-30T08:00:27+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/fas-3-programmet-dissolve-med-sel-212-vid-kronisk-gikt-uppnar-primara-effektmatt 2023-03-21T08:28:20+01:00 0.5 https://www.sobi.com/en/press-releases/phase-3-dissolve-program-sel-212-chronic-refractory-gout-meets-primary-endpoint 2023-03-21T08:28:20+01:00 0.5 https://www.sobi.com/en/press-releases/positive-topline-results-pivotal-xtend-kids-phase-3-study-efanesoctocog-alfa 2023-03-02T08:00:32+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/positiva-topline-resultat-fran-den-pivotala-fas-3-studien-xtend-kids-med 2023-03-02T08:00:31+01:00 0.5 https://www.sobi.com/en/press-releases/fda-approves-once-weekly-efanesoctocog-alfa-new-class-high-sustained-factor-viii 2023-02-23T22:15:21+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/fda-godkanner-efanesoctocog-alfa-en-ny-klass-av-faktorkoncentrat-med-langvarigt 2023-02-23T22:15:21+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-publicerar-delarsrapport-fjarde-kvartalet-och-bokslutskommunike-2022-ett-bra 2023-02-09T11:05:11+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-publishes-q4-and-fy-2022-report-good-year-and-solid-future-2091405 2023-02-09T11:04:08+01:00 0.5 https://www.sobi.com/en/financial-reports/sobi-publishes-q4-and-fy-2022-report-good-year-and-solid-future 2023-02-09T11:01:05+01:00 0.5 https://www.sobi.com/en/press-releases/changes-sobis-management-2089872 2023-02-02T08:00:22+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/ledningsforandring-i-sobi-2089866 2023-02-02T08:00:21+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/inbjudan-sobis-delarsrapport-fjarde-kvartalet-och-bokslutskommunike-2022-2088243 2023-01-27T11:00:29+01:00 0.5 https://www.sobi.com/en/press-releases/invitation-sobis-q4-and-fy-2022-report-2088242 2023-01-27T11:00:19+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/nejm-publicerar-data-som-visar-kliniskt-meningsfull-prevention-av-blodningar-och 2023-01-26T11:00:14+01:00 0.5 https://www.sobi.com/en/press-releases/nejm-publishes-data-demonstrating-clinically-meaningful-prevention-bleeds-and 2023-01-26T11:00:09+01:00 0.5 https://www.sobi.com/en/sobi-websites 2022-12-29T10:02:03+01:00 0.5 https://www.sobi.com/en/press-releases/zynlontar-loncastuximab-tesirine-approved-eu-treatment-relapsed-or-refractory 2022-12-21T08:00:23+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/zynlontar-loncastuximab-tesirine-godkant-i-eu-behandling-av-recidiverande-eller 2022-12-21T08:00:23+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/delarsrapport-jan-sep-2021 2022-11-30T13:10:51+01:00 0.5 https://www.sobi.com/en/financial-reports/interim-report-q3-2021 2022-11-30T12:33:07+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/bokslutskommunike-2019 2022-11-29T10:02:53+01:00 0.5 https://www.sobi.com/en/financial-reports/report-q4-and-full-year-2019 2022-11-29T10:02:40+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/bo-jesper-hansen-foreslas-till-ny-styrelseordforande-i-swedish-orphan-biovitrum-ab 2022-11-18T15:34:15+01:00 0.5 https://www.sobi.com/en/press-releases/bo-jesper-hansen-proposed-new-chairman-board-swedish-orphan-biovitrum-ab-publ-ahead 2022-11-18T15:34:15+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrum-biovitrums-delarsrapport-januari-september-2006-1412787 2022-11-14T10:39:49+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/biovitrum-biovitrums-delarsrapport-januari-september-2006 2022-11-14T10:39:49+01:00 0.5 https://www.sobi.com/en/financial-reports/interim-report-q3-2017 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/delarsrapport-jan-sep-2017 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/en/financial-reports/interim-report-q2-2017 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/delarsrapport-jan-jun-2017 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/en/financial-reports/interim-report-q1-2017 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/delarsrapport-jan-mar-2017 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/arsredovisning-2016 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/en/financial-reports/annual-report-2016 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/bokslutskommuniken-2016 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/en/financial-reports/report-q4-and-full-year-2016 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/delarsrapport-jan-sep-2016 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/en/financial-reports/interim-report-q3-2016 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/en/financial-reports/interim-report-q2-2016 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/delarsrapport-jan-jun-2016 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/en/financial-reports/interim-report-q1-2016 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/delarsrapport-jan-mar-2016 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/en/financial-reports/annual-report-2015 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/arsredovisning-2015 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/bokslutskommuniken-2015 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/en/financial-reports/report-q4-and-full-year-2015 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/delarsrapport-jan-sep-2015 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/en/financial-reports/interim-report-q3-2015 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/en/financial-reports/interim-report-q2-2015 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/delarsrapport-jan-jun-2015 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/delarsrapport-jan-mar-2015 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/en/financial-reports/interim-report-q1-2015 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/en/financial-reports/annual-report-2014 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/arsredovisning-2014 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/en/financial-reports/report-q4-and-full-year-2014 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/bokslutskommunike-2014 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/en/financial-reports/interim-report-q3-2014 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/delarsrapport-jan-sep-2014 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/en/financial-reports/interim-report-q2-2014 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/delarsrapport-jan-jun-2014 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/delarsrapport-jan-mar-2014 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/en/financial-reports/interim-report-q1-2014 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/en/financial-reports/annual-report-2013 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/arsredovisning-2013 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/en/financial-reports/report-q4-and-full-year-2013 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/bokslutskommunike-2013 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/en/financial-reports/interim-report-q3-2013 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/delarsrapport-jan-sep-2013 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/en/financial-reports/interim-report-q2-2013 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/delarsrapport-jan-jun-2013 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/delarsrapport-jan-mar-2013 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/en/financial-reports/interim-report-q1-2013 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/arsredovisning-2012 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/en/financial-reports/annual-report-2012 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/bokslutskommuniken-2012 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/en/financial-reports/report-q4-and-full-year-2012 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/delarsrapport-jan-sep-2012 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/en/financial-reports/interim-report-q3-2012 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/en/financial-reports/interim-report-q2-2012 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/delarsrapport-jan-jun-2012 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/en/financial-reports/interim-report-q1-2012 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/delarsrapport-jan-mar-2012 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/en/financial-reports/annual-report-2011 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/arsredovisning-2011 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/bokslutskommuniken-2011 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/en/financial-reports/report-q4-and-full-year-2011 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/en/financial-reports/interim-report-q3-2011 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/delarsrapport-jan-sep-2011 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/delarsrapport-jan-jun-2011 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/en/financial-reports/interim-report-q2-2011 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/delarsrapport-jan-mar-2011 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/en/financial-reports/interim-report-q1-2011 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/en/financial-reports/report-q4-and-full-year-2010 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/swedish-orphan-biovitrum-bokslutskommunike-2010 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/delarsrapport-perioden-1-januari-till-30-september-2010 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/en/financial-reports/interim-report-q3-2010 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/en/financial-reports/interim-report-q2-2010 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/delarsrapport-perioden-1-april-till-30-juni-2010 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/en/financial-reports/interim-report-q1-2010 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/delarsrapport-perioden-1-januari-till-31-mars-2010 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/biovitrum-delarsrapport-1-januari-30-september-2009 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/en/financial-reports/biovitrum-interim-report-january-1st-september-30th-2009 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/delarsrapport-1-januari-30-juni-2009 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/en/financial-reports/interim-report-1st-april-30th-june-2009 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/en/financial-reports/biovitrum-interim-report-1st-january-31st-march-2009 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/biovitrums-delarsrapport-1-januari-31-mars-2009 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/biovitrum-bokslutskommunike-2008 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/en/financial-reports/biovitrum-full-year-report-2008 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/en/financial-reports/biovitrum-interim-report-january-1-september-30-2008 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/finansiellt-starkt-tredje-kvartal-produktforvarv-fran-amgen-banarvag-utvidgad 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/en/financial-reports/biovitrum-interim-report-january-1-june-30-2008 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/biovitrum-delarsrapport-1-januari-30-juni-2008 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/en/financial-reports/biovitrum-interim-report-january-1-march-31-2008 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/biovitrum-delarsrapport-1-januari-31-mars-2008 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/en/financial-reports/biovitrum-full-year-report-2007 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/biovitrum-bokslutskommunike-2007 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/biovitrum-delarsrapport-1-januari-30-september-2007 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/en/financial-reports/biovitrum-interim-report-january-1-september-30-2007 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/en/financial-reports/biovitrum-interim-report-january-1-june-30-2007 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/biovitrum-delarsrapport-1-januari-30-juni-2007 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/biovitrums-delarsrapport-januari-mars-2007 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/en/financial-reports/biovitrums-interim-report-january-march-2007 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/biovitrums-bokslutskommunike-2006 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/en/financial-reports/biovitrum-full-year-report-2006 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/en/financial-reports/biovitrum-biovitrums-interim-report-january-september-2006 2022-11-14T10:31:46+01:00 0.5 https://www.sobi.com/en/financial-reports/interim-report-q3-2019 2022-11-14T10:29:52+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/delarsrapport-jan-sep-2019 2022-11-14T10:29:52+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/delarsrapport-jan-jun-2019 2022-11-14T10:29:52+01:00 0.5 https://www.sobi.com/en/financial-reports/interim-report-q2-2019 2022-11-14T10:29:52+01:00 0.5 https://www.sobi.com/en/financial-reports/interim-report-q1-2019 2022-11-14T10:29:52+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/delarsrapport-jan-mar-2019 2022-11-14T10:29:52+01:00 0.5 https://www.sobi.com/en/financial-reports/annual-and-sustainability-report-2018 2022-11-14T10:29:52+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/ars-och-hallbarhetsredovisning-2018 2022-11-14T10:29:52+01:00 0.5 https://www.sobi.com/en/financial-reports/report-q4-and-full-year-2018 2022-11-14T10:29:52+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/bokslutskommuniken-2018 2022-11-14T10:29:52+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/delarsrapport-jan-sep-2018 2022-11-14T10:29:52+01:00 0.5 https://www.sobi.com/en/financial-reports/interim-report-q3-2018 2022-11-14T10:29:52+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/delarsrapport-jan-jun-2018 2022-11-14T10:29:52+01:00 0.5 https://www.sobi.com/en/financial-reports/interim-report-q2-2018 2022-11-14T10:29:52+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/delarsrapport-jan-mar-2018 2022-11-14T10:29:52+01:00 0.5 https://www.sobi.com/en/financial-reports/interim-report-q1-2018 2022-11-14T10:29:52+01:00 0.5 https://www.sobi.com/en/financial-reports/annual-and-sustainability-report-2017 2022-11-14T10:29:52+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/ars-och-hallbarhetsredovisning-2017 2022-11-14T10:29:52+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/bokslutskommuniken-2017 2022-11-14T10:29:52+01:00 0.5 https://www.sobi.com/en/financial-reports/report-q4-and-full-year-2017 2022-11-14T10:29:52+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/delarsrapport-jan-jun-2021 2022-11-14T10:28:38+01:00 0.5 https://www.sobi.com/en/financial-reports/interim-report-q2-2021 2022-11-14T10:28:38+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/delarsrapport-jan-mar-2021 2022-11-14T10:28:38+01:00 0.5 https://www.sobi.com/en/financial-reports/interim-report-q1-2021 2022-11-14T10:28:38+01:00 0.5 https://www.sobi.com/en/financial-reports/annual-and-sustainability-report-2020 2022-11-14T10:28:38+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/ars-och-hallbarhetsredovisning-2020 2022-11-14T10:28:38+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/bokslutskommunike-2020 2022-11-14T10:28:38+01:00 0.5 https://www.sobi.com/en/financial-reports/report-q4-and-full-year-2020 2022-11-14T10:28:38+01:00 0.5 https://www.sobi.com/en/financial-reports/interim-report-q3-2020 2022-11-14T10:28:38+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/delarsrapport-jan-sep-2020 2022-11-14T10:28:38+01:00 0.5 https://www.sobi.com/en/financial-reports/interim-report-q2-2020 2022-11-14T10:28:38+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/delarsrapport-jan-jun-2020 2022-11-14T10:28:38+01:00 0.5 https://www.sobi.com/en/financial-reports/interim-report-q1-2020 2022-11-14T10:28:38+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/delarsrapport-jan-mar-2020 2022-11-14T10:28:38+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/ars-och-hallbarhetsredovisning-2019 2022-11-14T10:28:38+01:00 0.5 https://www.sobi.com/en/financial-reports/annual-and-sustainability-report-2019 2022-11-14T10:28:38+01:00 0.5 https://www.sobi.com/en/financial-reports/interim-report-q3-2022 2022-11-14T10:27:42+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/delarsrapport-jan-sept-2022 2022-11-14T10:27:42+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/delarsrapport-jan-juni-2022 2022-11-14T10:27:42+01:00 0.5 https://www.sobi.com/en/financial-reports/interim-report-q2-2022 2022-11-14T10:27:42+01:00 0.5 https://www.sobi.com/en/financial-reports/interim-report-q1-2022 2022-11-14T10:27:42+01:00 0.5 https://www.sobi.com/sv/finansiella-rapporter/delarsrapport-jan-mar-2022 2022-11-14T10:27:42+01:00 0.5 https://www.sobi.com/en/financial-reports/annual-and-sustainability-report-2021 2022-11-14T10:27:42+01:00 0.5 https://www.sobi.com/en/financial-reports/report-q4-and-full-year-2021 2022-11-14T10:27:42+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/kineretr-godkant-av-fda-nodanvandning-i-usa-vid-behandling-av-patienter-med-covid 2022-11-10T13:00:19+01:00 0.5 https://www.sobi.com/en/press-releases/kineretr-authorised-emergency-use-fda-treatment-covid-19-related-pneumonia-2067733 2022-11-10T13:00:14+01:00 0.5 https://www.sobi.com/en/press-releases/biovitrum-issue-new-shares-biovitrum-ab-publ-w-1412778 2022-11-03T11:01:27+01:00 0.5 https://www.sobi.com/en/press-releases/biovitrum-issue-new-shares-biovitrum-ab-publ-1412781 2022-11-03T11:01:27+01:00 0.5 https://www.sobi.com/en/press-releases/biovitrum-new-organisation-biovitrum-1412779 2022-11-03T11:01:27+01:00 0.5 https://www.sobi.com/en/press-releases/biovitrum-head-rd-anders-ullman-leaves-biovitrum-1412782 2022-11-03T11:01:27+01:00 0.5 https://www.sobi.com/en/press-releases/biovitrum-issue-new-shares-biovitrum-ab-publ-1412776 2022-11-03T11:01:27+01:00 0.5 https://www.sobi.com/en/press-releases/biovitrum-issue-new-shares-biovitrum-ab-publ-1412790 2022-11-03T11:01:27+01:00 0.5 https://www.sobi.com/en/press-releases/biovitrum-presentation-interim-report-invitation-p-1412794 2022-11-03T11:01:27+01:00 0.5 https://www.sobi.com/en/press-releases/biovitrum-biovitrum-wins-contract-manufacture-pharmac-1412795 2022-11-03T11:01:27+01:00 0.5 https://www.sobi.com/en/press-releases/biovitrum-issue-new-shares-biovitrum-ab-publ-1412791 2022-11-03T11:01:27+01:00 0.5 https://www.sobi.com/en/press-releases/biovitrum-issue-new-shares-biovitrum-ab-publ-1412798 2022-11-03T11:01:27+01:00 0.5 https://www.sobi.com/en/press-releases/biovitrum-issue-new-shares-biovitrum-ab-publ-1412800 2022-11-03T11:01:27+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrum-biovitrum-presenterar-pa-den-25e-arliga-jpmor-1412772 2022-11-03T11:01:27+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrum-nyemission-i-biovitrum-ab-publ-optionsprog-1412777 2022-11-03T11:01:27+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrum-nyemission-i-biovitrum-ab-publ-1412775 2022-11-03T11:01:27+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrum-ny-organisation-i-biovitrum-1412783 2022-11-03T11:01:27+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrum-fou-chef-anders-ullman-lamnar-biovitrum-1412780 2022-11-03T11:01:27+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrum-nyemission-i-biovitrum-ab-publ-1412788 2022-11-03T11:01:27+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrum-nyemission-i-biovitrum-ab-publ-1412793 2022-11-03T11:01:27+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrum-issue-new-shares-biovitrum-ab-publ-1412785 2022-11-03T11:01:27+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrum-nyemission-i-biovitrum-ab-publ-1412784 2022-11-03T11:01:27+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrum-presentation-av-delarsrapport-inbjudan-till-pr-1412792 2022-11-03T11:01:27+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrum-biovitrum-far-uppdrag-att-tillverka-lakemedels-1412789 2022-11-03T11:01:27+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrum-nyemission-i-biovitrum-ab-publ-1412801 2022-11-03T11:01:27+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrum-nyemission-i-biovitrum-ab-publ-1412796 2022-11-03T11:01:27+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrum-nyemission-i-biovitrum-ab-publ-1412797 2022-11-03T11:01:27+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrum-nyemission-i-biovitrum-ab-publ-1412805 2022-11-03T11:01:27+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrum-nyemission-i-biovitrum-ab-publ-1412803 2022-11-03T11:01:27+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrum-biovitrum-ingar-utvecklingsavtal-med-det-svens-1412807 2022-11-03T11:01:27+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrum-nyemission-i-biovitrum-ab-publ-1412808 2022-11-03T11:01:27+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrum-nyemission-i-biovitrum-ab-publ-1412804 2022-11-03T11:01:27+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrum-nyemission-i-biovitrum-ab-publ-1412802 2022-11-03T11:01:27+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrum-biovitrum-meddelande-om-utnyttjande-om-overt-1412806 2022-11-03T11:01:27+01:00 0.5 https://www.sobi.com/en/press-releases/biovitrum-has-successfully-completed-first-phase-i-trial-its5-ht6-receptor 2022-11-03T11:01:08+01:00 0.5 https://www.sobi.com/en/press-releases/results-biovitrums-phase-ii-clinical-trial-novel-paintreatment-expected-be-presented 2022-11-03T11:01:08+01:00 0.5 https://www.sobi.com/en/press-releases/biovitrum-announces-future-roadmap-increased-focus-specialistcare-diseases-1412843 2022-11-03T11:01:08+01:00 0.5 https://www.sobi.com/en/press-releases/invitation-presentation-interim-report-january-june-2007-1412748 2022-11-03T11:01:08+01:00 0.5 https://www.sobi.com/en/press-releases/biovitrum-strengthens-its-relationship-wyeth-starts-co-promote-benefixr-nordic 2022-11-03T11:01:08+01:00 0.5 https://www.sobi.com/en/press-releases/biovitrum-strengthens-its-relationship-wyeth-starts-co-promote-benefixr-nordic-0 2022-11-03T11:01:08+01:00 0.5 https://www.sobi.com/en/press-releases/biovitrum-terminates-preclinical-program-obesity-all-rights-are-returned 2022-11-03T11:01:08+01:00 0.5 https://www.sobi.com/en/press-releases/resolutions-biovitrums-agm-1412753 2022-11-03T11:01:08+01:00 0.5 https://www.sobi.com/en/press-releases/biovitrum-initiates-phase-ii-clinical-trial-novel-pain-treatment-1412752 2022-11-03T11:01:08+01:00 0.5 https://www.sobi.com/en/press-releases/invitation-press-and-analyst-meeting-and-conference-call-1412758 2022-11-03T11:01:08+01:00 0.5 https://www.sobi.com/en/press-releases/biovitrums-annual-report-and-business-review-2006-1412761 2022-11-03T11:01:08+01:00 0.5 https://www.sobi.com/en/press-releases/martin-nicklasson-new-ceo-and-president-biovitrum-1412762 2022-11-03T11:01:08+01:00 0.5 https://www.sobi.com/en/press-releases/notice-annual-general-meeting-biovitrum-ab-publmay-3-2007-1412769 2022-11-03T11:01:08+01:00 0.5 https://www.sobi.com/en/press-releases/board-directors-dividend-proposal-annual-general-meeting-biovitrum-1412766 2022-11-03T11:01:08+01:00 0.5 https://www.sobi.com/en/press-releases/biovitrum-biovitrum-launches-new-drug-nordic-countrie-1412771 2022-11-03T11:01:08+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrum-har-framgangsrikt-genomfort-fas-i-studie-med5-ht6-receptorantagonist 2022-11-03T11:01:08+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/resultaten-av-biovitrums-kliniska-fas-ii-studie-av-ny-metod-forsmartbehandling 2022-11-03T11:01:08+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrum-tillkannager-framtida-vagval-okar-fokus-pa-sjukdomar-somkraver 2022-11-03T11:01:08+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/inbjudan-presentation-av-delarsrapport-januari-juni-2007-1412749 2022-11-03T11:01:08+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrum-starker-relationen-med-wyeth-borjar-marknadsfora-lakemedlet-benefixr-i 2022-11-03T11:01:08+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrum-avslutar-prekliniskt-program-inom-fetma-far-tillbaka-rattigheterna-fran 2022-11-03T11:01:08+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/kommunike-fran-biovitrums-arsstamma-1412755 2022-11-03T11:01:08+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrum-inleder-klinisk-fas-ii-studie-av-ny-metod-smartbehandling-1412745 2022-11-03T11:01:08+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/inbjudan-till-press-och-analytikermote-samt-telefonkonferens-1412759 2022-11-03T11:01:08+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrums-arsredovisning-och-arsberattelse-2006-1412757 2022-11-03T11:01:08+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/martin-nicklasson-ny-vd-och-koncernchef-i-biovitrum-1412765 2022-11-03T11:01:08+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/kallelse-till-arsstamma-i-biovitrum-ab-publ-den-3-maj-2007-1412767 2022-11-03T11:01:08+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/styrelsens-utdelningsforslag-till-biovitrums-arsstamma-1412763 2022-11-03T11:01:08+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrum-biovitrum-och-synphora-inleder-fas-ii-studie-f-1412770 2022-11-03T11:01:08+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrum-biovitrum-and-synphora-initiate-phase-ii-study-1412773 2022-11-03T11:01:08+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrum-biovitrum-lanserar-nytt-lakemedel-i-norden-mot-1412774 2022-11-03T11:01:08+01:00 0.5 https://www.sobi.com/en/press-releases/board-directors-biovitrum-utilizes-authorization-torepurchase-shares-secure-0 2022-11-03T11:00:20+01:00 0.5 https://www.sobi.com/en/press-releases/new-share-issue-biovitrum-ab-publ-1412726 2022-11-03T11:00:20+01:00 0.5 https://www.sobi.com/en/press-releases/biovitrum-and-amgen-announce-close-product-acquisition-deal-1412729 2022-11-03T11:00:20+01:00 0.5 https://www.sobi.com/en/press-releases/biovitrums-and-syntonixs-novel-factor-ixfc-hemophilia-b-hasreceived-orphan-drug 2022-11-03T11:00:20+01:00 0.5 https://www.sobi.com/en/press-releases/biovitrum-and-symphogen-report-positive-clinical-results-novelrh-immunization 2022-11-03T11:00:20+01:00 0.5 https://www.sobi.com/en/press-releases/biovitrum-extends-refactor-supply-agreement-wyeth-until-december31-2015-1412733 2022-11-03T11:00:20+01:00 0.5 https://www.sobi.com/en/press-releases/new-share-issue-biovitrum-ab-publ-1412738 2022-11-03T11:00:20+01:00 0.5 https://www.sobi.com/en/press-releases/biovitrum-begins-exinaldatm-study-cystic-fibrosis-patientswith-fat-malabsorption 2022-11-03T11:00:20+01:00 0.5 https://www.sobi.com/en/press-releases/biovitrum-acquire-kepivancer-and-stemgenr-and-exclusively-licensekineretr-amgen 2022-11-03T11:00:20+01:00 0.5 https://www.sobi.com/en/press-releases/symphogen-and-biovitrum-have-initiated-novel-treatment-study-inautoimmune-bleeding 2022-11-03T11:00:20+01:00 0.5 https://www.sobi.com/en/press-releases/biovitrum-and-syntonix-dose-first-hemophilia-b-patient-clinicaltrial-novel-factor 2022-11-03T11:00:20+01:00 0.5 https://www.sobi.com/en/press-releases/biovitrum-implements-strategic-restructuring-rd-organization-1412819 2022-11-03T11:00:20+01:00 0.5 https://www.sobi.com/en/press-releases/resolutions-biovitrums-agm-1412817 2022-11-03T11:00:20+01:00 0.5 https://www.sobi.com/en/press-releases/biovitrum-and-symphogen-initiates-second-clinical-study-anovel-treatment-hemolytic 2022-11-03T11:00:20+01:00 0.5 https://www.sobi.com/en/press-releases/biovitrums-unique-neuropathic-pain-compound-very-safe-and-showspositive-effect 2022-11-03T11:00:20+01:00 0.5 https://www.sobi.com/en/press-releases/first-premature-infant-recruited-kiobrina-study-triggersmilestone-payment-biovitrum 2022-11-03T11:00:20+01:00 0.5 https://www.sobi.com/en/press-releases/notice-annual-general-meeting-biovitrum-ab-publ-april-242008-1412832 2022-11-03T11:00:20+01:00 0.5 https://www.sobi.com/en/press-releases/biovitrum-and-syntonix-set-begin-phase-iiia-clinical-trial-oflong-acting-recombinant 2022-11-03T11:00:20+01:00 0.5 https://www.sobi.com/en/press-releases/biovitrum-has-completed-exploratory-clinical-phase-ii-study-inglaucoma-1412827 2022-11-03T11:00:20+01:00 0.5 https://www.sobi.com/en/press-releases/biovitrum-and-symphogen-have-successfully-completed-phase-i-clinicaltrial 2022-11-03T11:00:20+01:00 0.5 https://www.sobi.com/en/press-releases/biovitrum-makes-first-move-focus-specialist-care-diseases-1412840 2022-11-03T11:00:20+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/styrelsen-i-biovitrum-utnyttjar-aterkopsbemyndigande-sakring-avbolagets-0 2022-11-03T11:00:20+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/nyemission-i-biovitrum-ab-publ-1412725 2022-11-03T11:00:20+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrum-och-amgen-slutfor-avtal-om-produktforvarv-1412730 2022-11-03T11:00:20+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrums-och-syntonix-unika-faktor-ixfc-behandling-av-hemofilib-har-fatt 2022-11-03T11:00:20+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrum-och-symphogen-rapporterar-positiva-resultat-fran-kliniskstudie-med-rh 2022-11-03T11:00:20+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrum-forlanger-leveransavtal-refactor-med-wyeth-fram-till-31december-2015 2022-11-03T11:00:20+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/nyemission-i-biovitrum-ab-publ-1412732 2022-11-03T11:00:20+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrum-inleder-exinaldatm-studie-i-cystisk-fibrospatienter-medbristande 2022-11-03T11:00:20+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrum-forvarvar-kepivancer-och-stemgenr-fran-amgen-samt-tecknaren-exklusiv 2022-11-03T11:00:20+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/symphogen-och-biovitrum-har-paborjat-studie-av-ny-behandling-ipatienter-med 2022-11-03T11:00:20+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrum-och-syntonix-behandlar-forsta-hemofili-b-patienten-iklinisk-studie-med 2022-11-03T11:00:20+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrum-genomfor-strategisk-omstrukturering-avforskningsorganisationen-1412821 2022-11-03T11:00:20+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/kommunike-fran-biovitrums-arsstamma-1412822 2022-11-03T11:00:20+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrum-och-symphogen-paborjar-en-andra-klinisk-studie-med-en-unikbehandling-av 2022-11-03T11:00:20+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrums-unika-substans-mot-nervsmarta-visar-hog-sakerhet-ochpositiv 2022-11-03T11:00:20+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/forsta-tidigt-fodda-barnet-rekryterat-i-kiobrina-studien-medformilstolpsersattning 2022-11-03T11:00:20+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/kallelse-till-arsstamma-i-biovitrum-ab-publ-den-24-april-2008-1412828 2022-11-03T11:00:20+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrum-och-syntonix-klara-att-inleda-fas-iiia-klinisk-studie-avlangtidsverkande 2022-11-03T11:00:20+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrum-har-slutfort-en-explorativ-klinisk-fas-ii-studie-avbehandling-mot-gron 2022-11-03T11:00:20+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrum-och-symphogen-har-framgangsrikt-slutfort-klinisk-fasi-provning-av 2022-11-03T11:00:20+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrum-tar-ytterligare-ett-steg-mot-fokusering-paspecialistlakemedel-1412841 2022-11-03T11:00:20+01:00 0.5 https://www.sobi.com/en/press-releases/biovitrum-ab-publ-makes-public-prospectus-supplement-1412655 2022-11-03T10:59:41+01:00 0.5 https://www.sobi.com/en/press-releases/biovitrum-sells-obesity-program-astrazeneca-1412650 2022-11-03T10:59:41+01:00 0.5 https://www.sobi.com/en/press-releases/biovitrum-advances-novel-factor-viii-long-acting-hemophilia-therapyinto-clinical 2022-11-03T10:59:41+01:00 0.5 https://www.sobi.com/en/press-releases/prospectus-regarding-biovitrums-preferential-rights-issue-nowavailable-1412659 2022-11-03T10:59:41+01:00 0.5 https://www.sobi.com/en/press-releases/mpm-capital-shows-commitment-and-full-support-biovitrumtransactions-1412656 2022-11-03T10:59:41+01:00 0.5 https://www.sobi.com/en/press-releases/mpm-capital-shows-commitment-and-full-support-biovitrumtransactions-1412657 2022-11-03T10:59:41+01:00 0.5 https://www.sobi.com/en/press-releases/press-release-extraordinary-shareholders-meeting-ofbiovitrum-publ-1412666 2022-11-03T10:59:41+01:00 0.5 https://www.sobi.com/en/press-releases/press-release-extraordinary-shareholders-meeting-ofbiovitrum-publ-1412670 2022-11-03T10:59:41+01:00 0.5 https://www.sobi.com/en/press-releases/board-directors-biovitrum-utilizes-authorization-torepurchase-shares-secure-companys 2022-11-03T10:59:41+01:00 0.5 https://www.sobi.com/en/press-releases/biovitrum-ab-publ-announces-terms-rights-issue-1412675 2022-11-03T10:59:41+01:00 0.5 https://www.sobi.com/en/press-releases/biovitrum-ab-publ-announces-terms-rights-issue-1412677 2022-11-03T10:59:41+01:00 0.5 https://www.sobi.com/en/press-releases/biovitrum-expands-kineretr-license-include-certain-orphanindications-1412676 2022-11-03T10:59:41+01:00 0.5 https://www.sobi.com/en/press-releases/kiobrinatm-shows-positive-phase-ii-results-preterm-infants-1412673 2022-11-03T10:59:41+01:00 0.5 https://www.sobi.com/en/press-releases/biovitrum-completes-divestiture-cambridge-biotechnology-1412674 2022-11-03T10:59:41+01:00 0.5 https://www.sobi.com/en/press-releases/notice-extra-ordinary-genral-meeting-biovitrum-ab-publ-4december-2009-1412682 2022-11-03T10:59:41+01:00 0.5 https://www.sobi.com/en/press-releases/creation-new-niche-specialty-pharmaceutical-company-focusedon-rare-diseases-strong 2022-11-03T10:59:41+01:00 0.5 https://www.sobi.com/en/press-releases/creation-new-niche-specialty-pharmaceutical-company-focusedon-rare-diseases-strong-0 2022-11-03T10:59:41+01:00 0.5 https://www.sobi.com/en/press-releases/biogen-idec-and-biovitrum-announce-decision-advance-long-actinghemophilia-b-therapy 2022-11-03T10:59:41+01:00 0.5 https://www.sobi.com/en/press-releases/new-number-shares-and-votes-biovitrum-ab-publ-1412689 2022-11-03T10:59:41+01:00 0.5 https://www.sobi.com/en/press-releases/biovitrum-selects-megapharm-distributor-israel-1412691 2022-11-03T10:59:41+01:00 0.5 https://www.sobi.com/en/press-releases/biovitrum-appoints-bank-new-york-mellon-depositary-bank-1412692 2022-11-03T10:59:41+01:00 0.5 https://www.sobi.com/en/press-releases/new-share-issue-biovitrum-ab-publ-1412694 2022-11-03T10:59:41+01:00 0.5 https://www.sobi.com/en/press-releases/biovitrum-transfers-two-metabolic-disease-projects-inovacia-1412700 2022-11-03T10:59:41+01:00 0.5 https://www.sobi.com/en/press-releases/new-share-issue-biovitrum-ab-publ-1412705 2022-11-03T10:59:41+01:00 0.5 https://www.sobi.com/en/press-releases/resolutions-biovitrums-agm-1412701 2022-11-03T10:59:41+01:00 0.5 https://www.sobi.com/en/press-releases/change-biovitrums-nomination-committee-1412706 2022-11-03T10:59:41+01:00 0.5 https://www.sobi.com/en/press-releases/notice-annual-general-meeting-biovitrum-ab-28-april-2009-1412710 2022-11-03T10:59:41+01:00 0.5 https://www.sobi.com/en/press-releases/biovitrum-gets-access-affibodyr-technology-1412715 2022-11-03T10:59:41+01:00 0.5 https://www.sobi.com/en/press-releases/biovitrum-enters-agreement-karolinska-development-1412712 2022-11-03T10:59:41+01:00 0.5 https://www.sobi.com/en/press-releases/new-number-shares-and-votes-biovitrum-ab-publ-1412716 2022-11-03T10:59:41+01:00 0.5 https://www.sobi.com/en/press-releases/changed-date-biovitrums-year-end-report-2008-1412719 2022-11-03T10:59:41+01:00 0.5 https://www.sobi.com/en/press-releases/biovitrum-aims-spin-out-cambridge-biotechnology-1412721 2022-11-03T10:59:41+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrum-ab-publ-offentliggor-tillaggsprospekt-1412651 2022-11-03T10:59:41+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrum-saljer-forskningsprogram-mot-fetma-till-astrazeneca-1412649 2022-11-03T10:59:41+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrum-avancerar-innovativ-langverkande-faktor-viii-hemofilia-behandling-i 2022-11-03T10:59:41+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/prospekt-biovitrums-foretradesemission-nu-tillgangligt-1412658 2022-11-03T10:59:41+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/mpm-capital-visar-engagemang-och-ger-biovitrums-transaktioner-sittfulla-stod 2022-11-03T10:59:41+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/mpm-capital-visar-engagemang-och-ger-biovitrums-transaktioner-sittfulla-stod-0 2022-11-03T10:59:41+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/kommunike-fran-extra-bolagsstamma-i-biovitrum-ab-publ-1412667 2022-11-03T10:59:41+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/kommunike-fran-extra-bolagsstamma-i-biovitrum-ab-publ-1412668 2022-11-03T10:59:41+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/styrelsen-i-biovitrum-utnyttjar-aterkopsbemyndigande-sakring-avbolagets 2022-11-03T10:59:41+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrum-ab-publ-offentliggor-villkor-foretradesemissionen-1412665 2022-11-03T10:59:41+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrum-ab-publ-offentliggor-villkor-foretradesemissionen-1412669 2022-11-03T10:59:41+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrum-utvidgar-licensen-kineretr-till-att-omfatta-vissasallsynta-sjukdomar 2022-11-03T10:59:41+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/kiobrinatm-uppvisar-positiva-fas-ii-resultat-i-tidigt-foddabarn-1412672 2022-11-03T10:59:41+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrum-slutfor-forsaljningen-av-cambridge-biotechnology-1412671 2022-11-03T10:59:41+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/kallelse-till-extra-bolagsstamma-i-biovitrum-ab-publ-den-4-december2009-1412681 2022-11-03T10:59:41+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/bildandet-av-ett-nytt-specialistlakemedelsforetag-fokuserat-paovanliga-sjukdomar 2022-11-03T10:59:41+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/bildandet-av-ett-nytt-specialistlakemedelsforetag-fokuserat-paovanliga-sjukdomar-0 2022-11-03T10:59:41+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biogen-idec-och-biovitrum-beslutar-ta-langverkande-hemofilib-behandling-i 2022-11-03T10:59:41+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/andring-av-antalet-aktier-och-roster-i-biovitrum-ab-publ-1412685 2022-11-03T10:59:41+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrum-utser-megapharm-som-distributor-i-israel-1412695 2022-11-03T10:59:41+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrum-utser-bank-new-york-mellon-som-depabank-1412696 2022-11-03T10:59:41+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/nyemission-i-biovitrum-ab-publ-1412699 2022-11-03T10:59:41+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrum-overlater-tva-projekt-inom-metabola-sjukdomar-till-inovacia-1412702 2022-11-03T10:59:41+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/nyemission-i-biovitrum-ab-publ-1412698 2022-11-03T10:59:41+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/kommunike-fran-biovitrums-arsstamma-1412703 2022-11-03T10:59:41+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/forandring-i-biovitrums-valberedning-1412708 2022-11-03T10:59:41+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/kallelse-till-biovitrum-abs-arsstamma-den-28-april-2009-1412707 2022-11-03T10:59:41+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrum-far-tillgang-till-affibodyr-teknologi-1412717 2022-11-03T10:59:41+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrum-traffar-avtal-med-karolinska-development-1412718 2022-11-03T10:59:41+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/andring-av-antalet-aktier-och-roster-i-biovitrum-ab-publ-1412713 2022-11-03T10:59:41+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/andrat-rapportdatum-biovitrums-bokslutskommunike-2008-1412720 2022-11-03T10:59:41+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrum-avyttrar-cambridge-biotechnology-1412724 2022-11-03T10:59:41+01:00 0.5 https://www.sobi.com/en/press-releases/swedish-orphan-biovitrum-returns-development-rights-sym001-symphogen-1412569 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/en/press-releases/board-directors-swedish-orphan-biovitrum-ab-publ-utilizes-authorization-repurchase 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/en/press-releases/swedish-orphan-biovitrums-long-lasting-hemophilia-therapy-receives-orphan-drug 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/en/press-releases/swedish-orphan-biovitrum-increase-availability-willfactr-von-willebrand-patients-lfb 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/en/press-releases/biogen-idec-and-swedish-orphan-biovitrum-announce-first-patient-dosed-global 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/en/press-releases/ceo-martin-nicklasson-leaves-swedish-orphan-biovitrum-1412578 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/en/press-releases/swedish-orphan-biovitrums-co-promotion-rights-mimparar-sold-back-amgen-1412581 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/en/press-releases/swedish-orphan-biovitrum-appoints-anders-edvell-new-head-sales-and-marketing-1412586 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/en/press-releases/swedish-orphan-biovitrum-and-dongbao-group-announce-distribution-agreement-iron 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/en/press-releases/new-number-shares-and-votes-swedish-orphan-biovitrum-ab-publ-1412588 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/en/press-releases/symphogen-and-swedish-orphan-biovitrum-receive-us-orphan-drug-designation 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/en/press-releases/swedish-orphan-biovitrums-hemophilia-therapy-receives-european-commission-orphan 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/en/press-releases/swedish-orphan-biovitrums-distribution-agreements-shire-be-discontinued-shire-sets 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/en/press-releases/new-number-shares-and-votes-swedish-orphan-biovitrum-ab-publ-1412599 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/en/press-releases/swedish-orphan-biovitrums-kineretr-has-received-orphan-drug-designation-usa-1412602 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/en/press-releases/biogen-idec-and-swedish-orphan-biovitrum-present-data-long-lasting-hemophilia-b 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/en/press-releases/biogen-idec-and-swedish-orphan-biovitrum-announce-decision-advance-long-lasting 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/en/press-releases/swedish-orphan-biovitrum-and-dongbao-announce-commercial-alliance-chinese-and 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/en/press-releases/change-company-name-biovitrum-ab-publ-1412603 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/en/press-releases/swedish-orphan-biovitrum-and-biomodels-develop-assay-mucositis-risk-cancer-treatment 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/en/press-releases/swedish-orphan-biovitrum-presents-first-positive-kiobrinar-clinical-phase-ii-data 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/en/press-releases/new-number-shares-and-votes-biovitrum-ab-publ-1412616 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/en/press-releases/resolutions-biovitrums-agm-1412620 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/en/press-releases/kiobrinar-clinical-phase-ii-results-trigger-milestone-payment-swedish-orphan 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/en/press-releases/swedish-orphan-biovitrum-has-decided-move-kiobrinar-phase-iii-development-1412628 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/en/press-releases/swedish-orphan-biovitrum-and-pharming-sign-rhucinr-distribution-agreement-1412626 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/en/press-releases/swedish-orphan-biovitrum-launches-willfactr-under-its-distribution-agreement-lfb 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/en/press-releases/swedish-orphan-biovitrum-makes-payment-vendors-cambridge-biotechnology-limited 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/en/press-releases/swedish-orphan-biovitrum-extends-cyanokitr-cooperation-merck-serono-1412632 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/en/press-releases/notice-annual-general-meeting-biovitrum-ab-publ-tuesday-april-27-2010-1412633 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/en/press-releases/swedish-orphan-biovitrum-updates-european-kepivancer-label-1412637 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/en/press-releases/swedish-orphan-biovitrum-has-agreed-additional-kineretr-drug-campaign-amgen-1412636 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/en/press-releases/biovitrum-full-year-report-2009-1412642 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/en/press-releases/biogen-idec-and-swedish-orphan-biovitrum-update-hemophilia-partnership-agreement 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/en/press-releases/new-number-shares-and-votes-biovitrum-ab-publ-1412647 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/en/press-releases/biogen-idec-and-swedish-orphan-biovitrum-announce-first-patient-dosed-global-0 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/en/press-releases/biovitrum-ab-publ-completes-acquisition-swedish-orphan-international-holding-ab-and 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/en/press-releases/biovitrum-abs-publ-rights-issue-fully-subscribed-1412653 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/swedish-orphan-biovitrum-aterlamnar-rattigheterna-utveckling-av-sym001-till 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/styrelsen-swedish-orphan-biovitrum-ab-publ-utnyttjar-aterkopsbemyndigande-sakring 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/swedish-orphan-biovitrums-langvariga-fviiifc-hemofili-behandling-erhaller-1412574 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/swedish-orphan-biovitrum-kommer-att-kunna-utoka-tillgangligheten-av-willfactr-till 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biogen-idec-and-swedish-orphan-biovitrum-meddelar-att-forsta-patienten-har 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/vd-martin-nicklasson-lamnar-swedish-orphan-biovitrum-1412580 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/swedish-orphan-biovitrums-co-promotionrattigheter-mimparar-atergar-till-amgen 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/swedish-orphan-biovitrum-utser-anders-edvell-till-ny-chef-marknad-och-forsaljning 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/swedish-orphan-biovitrum-och-dongbao-group-har-ingatt-ett-distributionsavtal-iron 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/andring-av-antalet-aktier-och-roster-i-swedish-orphan-biovitrum-ab-publ-1412587 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/symphogen-och-swedish-orphan-biovitrum-har-erhallit-sarlakemedelsstatus-i-usa 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/swedish-orphan-biovitrum-erhaller-sarlakemedelsklassificering-orphan-drug 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/swedish-orphan-biovitrums-distributionsavtal-med-shire-kommer-att-upphora-nar 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/andring-av-antalet-aktier-och-roster-i-swedish-orphan-biovitrum-ab-publ-1412596 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/swedish-orphan-biovitrums-kineretr-har-erhallit-sarlakemedelsstatus-i-usa-1412597 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biogen-idec-och-swedish-orphan-biovitrum-presenterar-data-langverkande-hemofili-b 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biogen-idec-och-swedish-orphan-biovitrum-beslutar-ta-langverkande-hemofili 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/swedish-orphan-biovitrum-och-dongbao-bildar-affarsallians-de-kinesiska-och 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/byte-av-bolagsnamn-biovitrum-ab-publ-1412604 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/swedish-orphan-biovitrum-och-biomodels-avser-att-utveckla-en-metod-identifiering 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/swedish-orphan-biovitrum-presenterar-positiva-data-fran-den-forsta-kliniska 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/andring-av-antalet-aktier-och-roster-i-biovitrum-ab-publ-1412614 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/kommunike-fran-biovitrums-arsstamma-1412613 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/kiobrinar-kliniska-fas-ii-resultat-medfor-milstolpsersattning-fran-swedish-orphan 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/swedish-orphan-biovitrum-har-beslutat-att-ga-vidare-med-kiobrinar-i-fas-iii 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/swedish-orphan-biovitrum-och-pharming-tecknar-avtal-om-distribution-av-rhucinr 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/swedish-orphan-biovitrum-lanserar-willfactr-inom-ramen-sitt-distributionsavtal-med 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/swedish-orphan-biovitrum-erlagger-betalning-till-tidigare-saljare-av-cambridge 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/swedish-orphan-biovitrum-utvidgar-samarbetet-med-merck-serono-runt-cyanokitr 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/kallelse-till-biovitrum-ab-publs-arsstamma-tisdagen-den-27-april-2010-1412634 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/swedish-orphan-biovitrum-uppdaterar-den-europeiska-indikationen-kepivancer-1412635 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/swedish-orphan-biovitrum-har-traffat-avtal-med-amgen-om-ytterligare 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrum-bokslutskommunike-2009-1412638 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biogen-idec-och-swedish-orphan-biovitrum-uppdaterar-avtal-om-hemofilisamarbete 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/andring-av-antalet-aktier-och-roster-i-biovitrum-ab-publ-1412646 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biogen-idec-och-swedish-orphan-biovitrum-har-inkluderat-forsta-patienten-i-global 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrum-ab-publ-fullbordar-forvarvet-av-swedish-orphan-international-holding-ab 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrum-abs-publ-foretradesemission-fulltecknad-1412654 2022-11-03T10:59:04+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-files-expand-kineretr-label-include-caps-1412455 2022-11-03T10:46:27+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-list-bond-loan-nasdaq-omx-stockholm-and-publishes-prospectus-1412458 2022-11-03T10:46:27+01:00 0.5 https://www.sobi.com/en/press-releases/biogen-idec-and-sobi-announce-positive-top-line-results-phase-3-study-investigating 2022-11-03T10:46:27+01:00 0.5 https://www.sobi.com/en/press-releases/jorgen-winroth-joins-sobi-lead-investor-relations-1412461 2022-11-03T10:46:27+01:00 0.5 https://www.sobi.com/en/press-releases/new-number-shares-and-votes-swedish-orphan-biovitrum-ab-publ-1412464 2022-11-03T10:46:27+01:00 0.5 https://www.sobi.com/en/press-releases/biogen-idec-and-sobi-announce-positive-top-line-results-phase-3-study-0 2022-11-03T10:46:27+01:00 0.5 https://www.sobi.com/en/press-releases/board-directors-exercises-authorization-repurchase-shares-purpose-securing-0 2022-11-03T10:46:27+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-enters-research-collaboration-affibody-within-il-1-field-1412477 2022-11-03T10:46:27+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-files-nomid-indication-kineret-us-1412474 2022-11-03T10:46:27+01:00 0.5 https://www.sobi.com/en/press-releases/biogen-idec-and-sobi-initiate-global-clinical-trials-long-lasting-hemophilia-and-b 2022-11-03T10:46:27+01:00 0.5 https://www.sobi.com/en/press-releases/change-number-shares-and-votes-swedish-orphan-biovitrum-ab-1412480 2022-11-03T10:46:27+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-issues-5-year-sek-600m-bond-1412478 2022-11-03T10:46:27+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-refinance-existing-credit-facility-1412484 2022-11-03T10:46:27+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-appoints-birgitte-volck-chief-medical-officer-1412483 2022-11-03T10:46:27+01:00 0.5 https://www.sobi.com/en/press-releases/sobiresolutions-swedish-orphan-biovitrums-sobi-annual-general-meeting-agm-1412487 2022-11-03T10:46:27+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-board-directors-exercises-authorization-share-issuance-and-repurchase-shares 2022-11-03T10:46:27+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-amends-its-agreement-sellers-arexis-ab-1412491 2022-11-03T10:46:27+01:00 0.5 https://www.sobi.com/en/press-releases/notice-annual-general-meeting-swedish-orphan-biovitrum-ab-publ-1412496 2022-11-03T10:46:27+01:00 0.5 https://www.sobi.com/en/press-releases/cfo-lars-sandstrom-leave-sobi-1412499 2022-11-03T10:46:27+01:00 0.5 https://www.sobi.com/en/press-releases/refacto-afrxynthar-supply-agreement-extended-until-2020-1412506 2022-11-03T10:46:27+01:00 0.5 https://www.sobi.com/en/press-releases/sobis-agreement-biogen-idec-regarding-long-lasting-rfviiifc-and-rfixfc-hemophilia 2022-11-03T10:46:27+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-wills-hughes-wilson-appointed-vice-president-government-affairs-policy-1412507 2022-11-03T10:46:27+01:00 0.5 https://www.sobi.com/en/press-releases/alan-raffensperger-appointed-chief-operating-officer-1412511 2022-11-03T10:46:27+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-signs-global-licensing-agreement-novel-neonatology-treatment-only-children 2022-11-03T10:46:27+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-ansoker-om-utvidgning-av-indikationen-kineretr-att-aven-omfatta-caps-1412452 2022-11-03T10:46:27+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-noterar-obligationslan-pa-nasdaq-omx-stockholm-och-offentliggor-prospekt 2022-11-03T10:46:27+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biogen-idec-och-sobi-meddelar-positiva-resultat-fran-fas-iii-studien-avseende 2022-11-03T10:46:27+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/jorgen-winroth-ansvarig-investor-relations-pa-sobi-1412462 2022-11-03T10:46:27+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/andring-av-antalet-aktier-och-roster-i-swedish-orphan-biovitrum-ab-publ-1412466 2022-11-03T10:46:27+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biogen-idec-and-sobi-meddelar-positiva-resultat-fran-fas-iii-studien-avseende 2022-11-03T10:46:27+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/styrelsen-utnyttjar-aterkopsbemyndigande-sakerstallande-av-bolagets-ataganden-6 2022-11-03T10:46:27+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-ingar-forskningssamarbete-med-affibody-inom-il-1-omradet-1412469 2022-11-03T10:46:27+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-ansoker-om-godkannande-av-kineret-nomid-i-usa-1412476 2022-11-03T10:46:27+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biogen-idec-och-sobi-initierar-globala-kliniska-barnstudier-med-langverkande 2022-11-03T10:46:27+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/andring-av-antalet-aktier-och-roster-i-swedish-orphan-biovitrum-ab-1412479 2022-11-03T10:46:27+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-emitterar-5-arigt-obligationslan-pa-600-mkr-1412482 2022-11-03T10:46:27+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-omfinansierar-befintlig-kreditfacilitet-1412481 2022-11-03T10:46:27+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-har-utnamnt-birgitte-volck-till-chief-medical-officer-1412486 2022-11-03T10:46:27+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-kommunike-fran-swedish-orphan-biovitrums-sobi-arsstamma-1412485 2022-11-03T10:46:27+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-styrelsen-utnyttjar-emissions-och-aterkopsbemyndigande-sakerstallande-av 2022-11-03T10:46:27+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-ingar-tillaggsavtal-med-saljarna-av-arexis-ab-1412495 2022-11-03T10:46:27+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/kallelse-till-arsstamma-i-swedish-orphan-biovitrum-ab-publ-1412497 2022-11-03T10:46:27+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/ekonomi-och-finansdirektor-lars-sandstrom-lamnar-sobi-1412498 2022-11-03T10:46:27+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/tillverkningsavtalet-med-pfizer-refacto-afrxyntha-forlangt-t-o-m-2020-1412502 2022-11-03T10:46:27+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobis-avtal-med-biogen-idec-avseende-hemofiliprogrammen-rfviiifc-och-rfixfc 2022-11-03T10:46:27+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-wills-hughes-wilson-utsedd-till-vice-president-government-affairs-policy 2022-11-03T10:46:27+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/alan-raffensperger-utsedd-till-chief-operating-officer-1412509 2022-11-03T10:46:27+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-tecknar-licensavtal-ny-behandling-inom-neonatalomradet-med-only-children 2022-11-03T10:46:27+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-temporarily-withdraw-new-drug-application-orfadinr-oral-suspension-us-1412385 2022-11-03T10:46:00+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-take-direct-responsibility-orfadin-us-canada-and-latin-america-1412384 2022-11-03T10:46:00+01:00 0.5 https://www.sobi.com/en/press-releases/swedish-orphan-biovitrum-ab-publ-new-phase-3-data-confirm-long-lasting 2022-11-03T10:46:00+01:00 0.5 https://www.sobi.com/en/press-releases/new-england-journal-medicine-publishes-pivotal-data-demonstrating-prophylactic 2022-11-03T10:46:00+01:00 0.5 https://www.sobi.com/en/press-releases/sobis-partner-biogen-idec-present-phase-3-data-prolonged-half-life-haemophilia 2022-11-03T10:46:00+01:00 0.5 https://www.sobi.com/en/press-releases/sobis-partner-biogen-idec-receives-notification-fda-pdufa-date-extension-alprolixtm 2022-11-03T10:46:00+01:00 0.5 https://www.sobi.com/en/press-releases/new-number-shares-and-votes-swedish-orphan-biovitrum-ab-publ-1412396 2022-11-03T10:46:00+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-receives-approval-kineretr-treatment-rare-disease-caps-1412397 2022-11-03T10:46:00+01:00 0.5 https://www.sobi.com/en/press-releases/sobis-partner-biogen-idec-expects-mid-2014-us-launch-eloctater-1412395 2022-11-03T10:46:00+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-hosts-capital-market-day-event-announces-phase-i-complement-inhibitor-program 2022-11-03T10:46:00+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-submits-application-orfadinr-oral-suspension-fda-1412405 2022-11-03T10:46:00+01:00 0.5 https://www.sobi.com/en/press-releases/new-number-shares-and-votes-swedish-orphan-biovitrum-ab-publ-1412409 2022-11-03T10:46:00+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-gains-rights-distribute-ravictir-named-patient-use-basis-middle-east-hyperion 2022-11-03T10:46:00+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-receives-positive-chmp-opinion-kineretr-treatment-rare-disease-caps-1412411 2022-11-03T10:46:00+01:00 0.5 https://www.sobi.com/en/press-releases/board-directors-exercises-authorization-repurchase-shares-purpose-securing-companys 2022-11-03T10:46:00+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-acquires-full-rights-kineretr-and-additional-clinical-data-kepivancer-amgen 2022-11-03T10:46:00+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-appoints-dennis-schmidt-pedersen-senior-vice-president-human-resources-1412416 2022-11-03T10:46:00+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-submits-application-orfadinr-oral-suspension-ema-1412419 2022-11-03T10:46:00+01:00 0.5 https://www.sobi.com/en/press-releases/auxilium-pharmaceuticals-inc-and-swedish-orphan-biovitrum-ab-publ-enter 2022-11-03T10:46:00+01:00 0.5 https://www.sobi.com/en/press-releases/biogen-idec-and-sobi-present-new-data-phase-3-study-their-long-lasting-haemophilia 2022-11-03T10:46:00+01:00 0.5 https://www.sobi.com/en/press-releases/biogen-idec-and-sobi-present-new-data-phase-3-study-their-long-lasting-haemophilia-0 2022-11-03T10:46:00+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-gets-fda-approval-manufacture-substance-kineretr-partner-boehringer-ingelheim 2022-11-03T10:46:00+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-appoints-mats-olof-wallin-permanent-chief-financial-officer-1412431 2022-11-03T10:46:00+01:00 0.5 https://www.sobi.com/en/press-releases/resolutions-sobis-annual-general-meeting-agm-1412433 2022-11-03T10:46:00+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-appoints-mats-olof-wallin-interim-chief-financial-officer-1412439 2022-11-03T10:46:00+01:00 0.5 https://www.sobi.com/en/press-releases/exelixis-selects-swedish-orphan-biovitrum-ab-cometriq-tm-european-distributor 2022-11-03T10:46:00+01:00 0.5 https://www.sobi.com/en/press-releases/sobis-additional-issuance-sek-200-million-under-current-bond-loan-fully-subscribed 2022-11-03T10:46:00+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-issue-additional-sek-200-million-under-current-bond-loan-1412442 2022-11-03T10:46:00+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-and-savient-pharmaceuticals-announce-co-promotion-agreement-kineretr-anakinra 2022-11-03T10:46:00+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-gains-distribution-rights-megacer-monoprilr-cefzilr-and-duricefr-pharmaswiss 2022-11-03T10:46:00+01:00 0.5 https://www.sobi.com/en/press-releases/new-phase-3-data-reinforce-long-lasting-protection-bleeding-patients-hemophilia-and 2022-11-03T10:46:00+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-drar-tillfalligt-tillbaka-sin-ansokan-om-en-flytande-formulering-av-orfadinr 2022-11-03T10:46:00+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-overtar-ansvaret-orfadin-i-usa-kanada-och-latinamerika-1412382 2022-11-03T10:46:00+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/swedish-orphan-biovitrum-ab-publ-ny-fas-3-data-bekraftar-forlangd-halveringstid 2022-11-03T10:46:00+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/forebyggande-injektioner-av-alprolixtm-motverkar-effektivt-blodningar-hos 2022-11-03T10:46:00+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobis-partner-biogen-idec-avser-att-presentera-fas-3-data-om-forlangd 2022-11-03T10:46:00+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobis-partner-biogen-idec-har-fatt-besked-av-fda-om-forskjuten-tidslinje 2022-11-03T10:46:00+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/andring-av-antalet-aktier-och-roster-i-swedish-orphan-biovitrum-ab-publ-1412394 2022-11-03T10:46:00+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-europeiska-kommissionen-godkanner-kineretr-behandling-av-caps-1412398 2022-11-03T10:46:00+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobis-partner-biogen-idec-raknar-med-lanseringen-av-eloctater-i-mitten-av-2014 2022-11-03T10:46:00+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-tillkannager-ny-klinisk-fas-i-provning-pa-kapitalmarknadsdag-1412399 2022-11-03T10:46:00+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-lamnar-ansokan-en-flytande-formulering-av-orfadinr-till-fda-1412403 2022-11-03T10:46:00+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/andring-av-antalet-aktier-och-roster-i-swedish-orphan-biovitrum-ab-publ-1412408 2022-11-03T10:46:00+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-far-rattigheterna-att-distribuera-ravictir-i-mellanostern-fran-hyperion 2022-11-03T10:46:00+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/chmp-rekommenderar-att-sobis-kineret-godkanns-behandling-av-caps-1412412 2022-11-03T10:46:00+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/styrelsen-utnyttjar-aterkopsbemyndigande-sakerstallande-av-bolagets-ataganden-5 2022-11-03T10:46:00+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-forvarvar-samtliga-rattigheter-kineretr-samt-kliniska-data-kepivancer-fran 2022-11-03T10:46:00+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-utser-dennis-schmidt-pedersen-till-personaldirektor-1412418 2022-11-03T10:46:00+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-lamnar-ansokan-en-flytande-formulering-av-orfadinr-till-ema-1412415 2022-11-03T10:46:00+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/auxilium-pharmaceuticals-inc-och-swedish-orphan-biovitrum-ab-publ-ingar 2022-11-03T10:46:00+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biogen-idec-och-sobi-presenterar-ny-data-fran-fas-3-studien-sin-langverkande 2022-11-03T10:46:00+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biogen-idec-och-sobi-presenterar-ny-data-fran-fas-3-studien-sin-langverkande-0 2022-11-03T10:46:00+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-far-fda-godkannande-att-tillverka-lakemedelssubstansen-kineretr-med-partnern 2022-11-03T10:46:00+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-utnamner-mats-olof-wallin-till-finansdirektor-1412428 2022-11-03T10:46:00+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/kommunike-fran-sobis-arsstamma-1412432 2022-11-03T10:46:00+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-utnamner-mats-olof-wallin-till-tillforordnad-finansdirektor-1412435 2022-11-03T10:46:00+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/exelixis-valjer-swedish-orphan-biovitrum-ab-som-europeisk-distributor-cometriq-tm 2022-11-03T10:46:00+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobis-ytterligare-emission-om-200-mkr-under-nuvarande-obligationslan-fulltecknad 2022-11-03T10:46:00+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-emitterar-ytterligare-upp-till-200-mkr-under-nuvarande-obligationslan-1412444 2022-11-03T10:46:00+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-och-savient-pharmaceuticals-tillkannager-marknadsforingsavtal-kineretr 2022-11-03T10:46:00+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-erhaller-distributionsrattigheter-megacer-monoprilr-cefzilr-och-duricefr-fran 2022-11-03T10:46:00+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/nya-fas-iii-resultat-stoder-langverkande-skydd-mot-blodning-patienter-med-hemofili 2022-11-03T10:46:00+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-exercises-opt-right-eloctatm-1412326 2022-11-03T10:45:38+01:00 0.5 https://www.sobi.com/en/press-releases/biogen-idec-and-sobi-announce-european-medicines-agency-validates-eloctatm-rfviiifc 2022-11-03T10:45:38+01:00 0.5 https://www.sobi.com/en/press-releases/sobis-collaboration-partner-biogen-idec-files-marketing-authorisation-application 2022-11-03T10:45:38+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-expands-haemophilia-development-portfolio-elects-include-potentially-longer 2022-11-03T10:45:38+01:00 0.5 https://www.sobi.com/en/press-releases/new-number-shares-and-votes-swedish-orphan-biovitrum-ab-publ-1412337 2022-11-03T10:45:38+01:00 0.5 https://www.sobi.com/en/press-releases/sobis-board-directors-exercises-authorisation-repurchase-shares-purpose-securing 2022-11-03T10:45:38+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-files-eu-approval-xiapex-peyronies-disease-1412343 2022-11-03T10:45:38+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-review-preclinical-data-potentially-add-future-haemophilia-candidate 2022-11-03T10:45:38+01:00 0.5 https://www.sobi.com/en/press-releases/us-food-and-drug-administration-fda-approves-eloctatetm-1412344 2022-11-03T10:45:38+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-establishes-north-american-office-massachusetts-1412347 2022-11-03T10:45:38+01:00 0.5 https://www.sobi.com/en/press-releases/swedish-orphan-biovitrum-ab-publ-sobi-appoints-kirsti-gjellan-senior-vice-president 2022-11-03T10:45:38+01:00 0.5 https://www.sobi.com/en/press-releases/biogen-idec-and-sobi-donate-1-billion-international-units-clotting-factor-support 2022-11-03T10:45:38+01:00 0.5 https://www.sobi.com/en/press-releases/swedish-orphan-biovitrum-ab-publ-annette-clancy-joins-sobis-board-directors-1412352 2022-11-03T10:45:38+01:00 0.5 https://www.sobi.com/en/press-releases/swedish-orphan-biovitrum-ab-publ-resolutions-sobis-agm-1412351 2022-11-03T10:45:38+01:00 0.5 https://www.sobi.com/en/press-releases/biogen-idec-and-sobi-announce-positive-top-line-efficacy-and-safety-results-phase-0 2022-11-03T10:45:38+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-becomes-market-authorisation-holder-xiapex-europe-1412361 2022-11-03T10:45:38+01:00 0.5 https://www.sobi.com/en/press-releases/notice-annual-general-meeting-swedish-orphan-biovitrum-ab-publ-1412372 2022-11-03T10:45:38+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-enters-partnership-tigenix-commercialisation-chondrocelect-1412368 2022-11-03T10:45:38+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-assumes-direct-responsibility-orfadinr-nitisinone-us-and-canada-and-introduces 2022-11-03T10:45:38+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-us-fda-approves-alprolixtm-1412374 2022-11-03T10:45:38+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-kiobrina-pivotal-phase-3-study-did-not-meet-primary-endpoint-1412378 2022-11-03T10:45:38+01:00 0.5 https://www.sobi.com/en/press-releases/cometriqr-approved-europe-treatment-progressive-unresectable-locally-advanced-or 2022-11-03T10:45:38+01:00 0.5 https://www.sobi.com/en/press-releases/health-canada-approves-alprolixtm-1412373 2022-11-03T10:45:38+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-utnyttjar-sin-option-pa-eloctatm-1412329 2022-11-03T10:45:38+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/europeiska-lakemedelsmyndigheten-validerar-ansokan-om-marknadsforingstillstand 2022-11-03T10:45:38+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobis-samarbetspartner-biogen-idec-ansoker-om-marknadsgodkannande-eloctatm 2022-11-03T10:45:38+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-utokar-utvecklingsportfolj-inom-hemofili-valjer-att-inkludera-potentiellt 2022-11-03T10:45:38+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/andring-av-antalet-aktier-och-roster-i-swedish-orphan-biovitrum-ab-publ-1412338 2022-11-03T10:45:38+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobis-styrelse-utnyttjar-aterkopsbemyndigande-sakerstallande-av-bolagets-ataganden 2022-11-03T10:45:38+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-ansoker-om-eu-godkannande-xiapex-vid-peyronies-sjukdom-1412342 2022-11-03T10:45:38+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-granskar-preklinisk-data-gallande-en-framtida-lakemedelskandidat-hemofili-att 2022-11-03T10:45:38+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/amerikanska-lakemedelsmyndigheten-fda-godkanner-eloctatetm-1412348 2022-11-03T10:45:38+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-flyttar-nordamerikansk-kontor-till-massachusetts-1412349 2022-11-03T10:45:38+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/swedish-orphan-biovitrum-ab-publ-sobi-utser-kirsti-gjellan-till-senior-vice 2022-11-03T10:45:38+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biogen-idec-och-sobi-donerar-en-miljard-internationella-enheter-koagulationsfaktor 2022-11-03T10:45:38+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/swedish-orphan-biovitrum-ab-publ-kommunike-fran-sobis-arsstamma-1412354 2022-11-03T10:45:38+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/swedish-orphan-biovitrum-ab-publ-annette-clancy-invald-i-sobis-styrelse-1412356 2022-11-03T10:45:38+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biogen-idec-och-sobi-meddelar-positiva-resultat-gallande-effekt-och-sakerhet-fran 2022-11-03T10:45:38+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-blir-innehavare-av-marknadsforingstillstandet-xiapex-i-europa-1412364 2022-11-03T10:45:38+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/kallelse-till-arsstamma-i-swedish-orphan-biovitrum-ab-publ-1412365 2022-11-03T10:45:38+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-ingar-partnerskap-med-tigenix-kommersialiseringen-av-chondrocelect-1412369 2022-11-03T10:45:38+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-overtar-ansvaret-orfadin-i-nordamerika-och-introducerar-orfadin4utm-1412367 2022-11-03T10:45:38+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-amerikanska-lakemedelsmyndigheten-fda-godkanner-alprolixtm-1412371 2022-11-03T10:45:38+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-kiobrinas-fas-3-studie-nadde-inte-det-primara-effektmattet-1412376 2022-11-03T10:45:38+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/cometriqr-godkant-i-europa-behandling-av-progressiv-inoperabel-lokalt-framskriden 2022-11-03T10:45:38+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/kanadensiska-lakemedelsmyndigheten-health-canada-godkanner-alprolixtm-1412375 2022-11-03T10:45:38+01:00 0.5 https://www.sobi.com/en/press-releases/lars-dreioe-joins-sobi-senior-vice-president-chief-quality-compliance-officer 2022-11-03T10:45:14+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-and-biogens-eloctar-rfviiifc-approved-europe-treatment-haemophilia-1412285 2022-11-03T10:45:14+01:00 0.5 https://www.sobi.com/en/press-releases/new-number-shares-and-votes-swedish-orphan-biovitrum-ab-publ-1412290 2022-11-03T10:45:14+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-ceo-invests-2015-lti-programme-and-divests-portion-incentive-shares-1412294 2022-11-03T10:45:14+01:00 0.5 https://www.sobi.com/en/press-releases/biogen-and-sobi-receive-positive-opinion-chmp-eloctatm-rfviiifc-treatment 2022-11-03T10:45:14+01:00 0.5 https://www.sobi.com/en/press-releases/swedish-orphan-biovitrum-ab-publ-board-directors-exercises-authorisation-repurchase 2022-11-03T10:45:14+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-exercises-opt-right-alprolixr-1412300 2022-11-03T10:45:14+01:00 0.5 https://www.sobi.com/en/press-releases/resolutions-sobis-annual-general-meeting-1412306 2022-11-03T10:45:14+01:00 0.5 https://www.sobi.com/en/press-releases/biogen-and-sobi-announce-european-medicines-agency-validates-alprolixr-rfixfc 2022-11-03T10:45:14+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-board-directors-terminates-discussions-regarding-non-binding-proposal-1412301 2022-11-03T10:45:14+01:00 0.5 https://www.sobi.com/en/press-releases/sobis-partner-biogen-submits-marketing-authorisation-application-alprolixr-rfixfc 2022-11-03T10:45:14+01:00 0.5 https://www.sobi.com/en/press-releases/notice-annual-general-meeting-swedish-orphan-biovitrum-ab-publ-1412308 2022-11-03T10:45:14+01:00 0.5 https://www.sobi.com/en/press-releases/sobis-board-directors-postpones-annual-general-meeting-shareholders-1412311 2022-11-03T10:45:14+01:00 0.5 https://www.sobi.com/en/press-releases/statement-regarding-recent-speculation-1412315 2022-11-03T10:45:14+01:00 0.5 https://www.sobi.com/en/press-releases/notice-annual-general-meeting-swedish-orphan-biovitrum-ab-publ-1412321 2022-11-03T10:45:14+01:00 0.5 https://www.sobi.com/en/press-releases/biogen-idec-and-sobi-announce-positive-top-line-efficacy-and-safety-results-phase-3 2022-11-03T10:45:14+01:00 0.5 https://www.sobi.com/en/press-releases/xiapex-approved-eu-commission-treatment-peyronies-disease-1412322 2022-11-03T10:45:14+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/lars-dreioe-blir-senior-vice-president-chief-quality-compliance-officer-pa-sobi 2022-11-03T10:45:14+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-och-biogens-eloctar-rfviiifc-godkand-i-europa-behandling-av-hemofili-1412282 2022-11-03T10:45:14+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/andring-av-antalet-aktier-och-roster-i-swedish-orphan-biovitrum-ab-publ-1412288 2022-11-03T10:45:14+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobis-vd-investerar-i-2015-ars-lti-program-och-avyttrar-del-av-insitamentsaktier 2022-11-03T10:45:14+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biogen-och-sobi-erhaller-chmp-rekommendation-eloctatm-rfviiifc-behandling-av 2022-11-03T10:45:14+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/swedish-orphan-biovitrum-ab-publ-styrelsen-utnyttjar-aterkopsbemyndigande 2022-11-03T10:45:14+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-utnyttjar-option-pa-alprolixr-1412298 2022-11-03T10:45:14+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/kommunike-fran-sobis-arsstamma-1412299 2022-11-03T10:45:14+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biogen-och-sobi-meddelar-att-den-europeiska-lakemedelsmyndigheten-validerat 2022-11-03T10:45:14+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobis-styrelse-avslutar-samtal-om-icke-bindande-forslag-1412302 2022-11-03T10:45:14+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobis-samarbetspartner-biogen-ansoker-om-marknadsgodkannande-alprolixr-rfixfc-i 2022-11-03T10:45:14+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/kallelse-till-arsstamma-i-swedish-orphan-biovitrum-ab-publ-1412309 2022-11-03T10:45:14+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobis-styrelse-senarelagger-arsstamman-1412312 2022-11-03T10:45:14+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/uttalande-angaende-pagaende-spekulationer-1412313 2022-11-03T10:45:14+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/kallelse-till-arsstamma-i-swedish-orphan-biovitrum-ab-publ-1412320 2022-11-03T10:45:14+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biogen-idec-och-sobi-meddelar-positiva-effekt-och-sakerhetsresultat-fran 2022-11-03T10:45:14+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/xiapexr-far-eu-godkannande-behandling-av-peyronies-sjukdom-1412324 2022-11-03T10:45:14+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-publishes-report-fourth-quarter-and-full-year-2019-1773375-0 2022-11-03T10:22:40+01:00 0.5 https://www.sobi.com/en/press-releases/swedish-orphan-biovitrum-ab-publs-chairman-board-hakan-bjorklund-will-not-be 2022-10-31T15:18:32+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/swedish-orphan-biovitrum-ab-publs-styrelseordforande-hakan-bjorklund-star-inte 2022-10-31T15:18:32+01:00 0.5 https://www.sobi.com/en/press-releases/biovitrum-full-year-report-2006-1412768-0 2022-10-31T13:21:44+01:00 0.5 https://www.sobi.com/en/press-releases/biovitrum-full-year-report-2007-1412834-0 2022-10-31T13:21:35+01:00 0.5 https://www.sobi.com/en/press-releases/biovitrum-full-year-report-2008-1412714-0 2022-10-31T13:21:26+01:00 0.5 https://www.sobi.com/en/press-releases/swedish-orphan-biovitrum-full-year-report-2010-1412561-0 2022-10-31T13:21:16+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-report-fourth-quarter-and-full-year-2011-1412501-0 2022-10-31T13:21:07+01:00 0.5 https://www.sobi.com/en/press-releases/report-fourth-quarter-and-full-year-2012-1412448-0 2022-10-31T13:20:58+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-publishes-its-report-fourth-quarter-and-full-year-2013-1412381-0 2022-10-31T13:20:50+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-publishes-its-report-fourth-quarter-and-full-year-2014-1412325-0 2022-10-31T13:20:41+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-publishes-its-report-fourth-quarter-and-full-year-2015-1412281-0 2022-10-31T13:20:32+01:00 0.5 https://www.sobi.com/en/press-releases/sobitm-publishes-its-report-fourth-quarter-and-full-year-2016-1465307-0 2022-10-31T13:20:23+01:00 0.5 https://www.sobi.com/en/press-releases/sobitm-publishes-its-report-fourth-quarter-and-full-year-2017-1553595-0 2022-10-31T13:20:13+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-publishes-report-fourth-quarter-and-full-year-2018-1661100-0 2022-10-31T13:20:01+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-publishes-report-fourth-quarter-and-full-year-2020-1886838-0 2022-10-31T13:19:45+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-publishes-q4-and-fy-2021-report-1987705-0 2022-10-31T13:19:35+01:00 0.5 https://www.sobi.com/en/press-releases/sobis-annual-report-2011-published-web-1412493-0 2022-10-31T13:19:08+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-publishes-2012-annual-report-1412437-0 2022-10-31T13:18:59+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-publishes-annual-report-2013-1412366-0 2022-10-31T13:18:50+01:00 0.5 https://www.sobi.com/en/press-releases/swedish-orphan-biovitrum-ab-publ-sobi-publishes-annual-report-2014-1412317-0 2022-10-31T13:18:42+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-publishes-2015-annual-report-1412854-0 2022-10-31T13:18:32+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-publishes-2016-annual-report-1480611-0 2022-10-31T13:18:24+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-publishes-2017-annual-and-sustainability-report-1568079-0 2022-10-31T13:18:15+01:00 0.5 https://www.sobi.com/en/press-releases/sobitm-publishes-2018-annual-and-sustainability-report-1679061-0 2022-10-31T13:18:06+01:00 0.5 https://www.sobi.com/en/press-releases/sobitm-publishes-2019-annual-and-sustainability-report-1797724-0 2022-10-31T13:17:58+01:00 0.5 https://www.sobi.com/en/press-releases/sobitm-publishes-2020-annual-and-sustainability-report-1903304-0 2022-10-31T13:17:48+01:00 0.5 https://www.sobi.com/en/press-releases/annual-and-sustainability-report-2021-2006669 2022-10-31T13:17:40+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobis-arsredovisning-2011-publicerad-pa-webben-1412492-0 2022-10-31T13:17:20+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobis-arsredovisning-2012-publicerad-1412440-0 2022-10-31T13:17:10+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobis-arsredovisning-2013-publicerad-1412363-0 2022-10-31T13:17:02+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/swedish-orphan-biovitrum-ab-publ-sobis-arsredovisning-2014-publicerad-1412316-1 2022-10-31T13:16:54+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-publicerar-arsredovisning-2015-1412853-0 2022-10-31T13:16:46+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-publicerar-arsredovisningen-2016-1480619-0 2022-10-31T13:16:37+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-publicerar-sin-ars-och-hallbarhetsredovisning-2017-1568076-0 2022-10-31T13:16:27+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobitm-publicerar-ars-och-hallbarhetsredovisningen-2018-1679059-0 2022-10-31T13:16:19+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobitm-publicerar-ars-och-hallbarhetsredovisningen-2019-1797722-0 2022-10-31T13:16:10+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobitm-publicerar-ars-och-hallbarhetsredovisningen-2020-1903303-0 2022-10-31T13:16:01+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/ars-och-hallbarhetsredovisningen-2021-2006673 2022-10-31T13:15:53+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrums-bokslutskommunike-2006-1412764-0 2022-10-31T13:15:30+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrum-bokslutskommunike-2007-1412836-0 2022-10-31T13:15:22+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrum-bokslutskommunike-2008-1412711-0 2022-10-31T13:15:12+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/swedish-orphan-biovitrum-bokslutskommunike-2010-1412563-0 2022-10-31T13:15:03+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-rapport-fjarde-kvartalet-och-helaret-2011-1412500-0 2022-10-31T13:14:55+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/rapport-fjarde-kvartalet-och-helaret-2012-1412450-0 2022-10-31T13:14:47+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-publicerar-sin-rapport-fjarde-kvartalet-och-bokslutskommunike-2013-1412380-0 2022-10-31T13:14:39+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-publicerar-sin-rapport-fjarde-kvartalet-och-bokslutskommunike-2014-1412323-0 2022-10-31T13:14:31+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-publicerar-sin-rapport-fjarde-kvartalet-samt-helaret-2015-1412278-0 2022-10-31T13:14:22+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobitm-publicerar-bokslutskommunike-2016-1465308-0 2022-10-31T13:14:11+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobitm-publicerar-bokslutskommuniken-2017-1553584-0 2022-10-31T13:14:02+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-publicerar-bokslutskommuniken-2018-1661101-0 2022-10-31T13:13:54+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-publicerar-bokslutskommuniken-2019-1773371-0 2022-10-31T13:13:44+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-publicerar-bokslutskommunike-2020-1886839-0 2022-10-31T13:13:34+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-publicerar-bokslutskommunike-2021-1987708-0 2022-10-31T13:13:23+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrums-delarsrapport-januari-mars-2007-1412756-0 2022-10-31T13:12:35+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrum-delarsrapport-1-januari-30-juni-2007-1412743-0 2022-10-31T13:12:28+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrum-delarsrapport-1-januari-30-september-2007-1412847-0 2022-10-31T13:12:19+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrum-delarsrapport-1-januari-31-mars-2008-1412825-0 2022-10-31T13:12:09+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrum-delarsrapport-1-januari-30-juni-2008-1412739-0 2022-10-31T13:12:01+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/finansiellt-starkt-tredje-kvartal-produktforvarv-fran-amgen-banarvag-utvidgad-0 2022-10-31T13:11:52+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrums-delarsrapport-1-januari-31-mars-2009-1412704-0 2022-10-31T13:11:41+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/delarsrapport-1-januari-30-juni-2009-1412693-0 2022-10-31T13:11:32+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/biovitrum-delarsrapport-1-januari-30-september-2009-1412686-0 2022-10-31T13:11:23+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/delarsrapport-perioden-1-januari-till-31-mars-2010-1412623-0 2022-10-31T13:11:14+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/delarsrapport-perioden-1-april-till-30-juni-2010-1412601-0 2022-10-31T13:11:06+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/delarsrapport-perioden-1-januari-till-30-september-2010-1412590-0 2022-10-31T13:10:57+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/delarsrapport-januari-mars-2011-1412549-0 2022-10-31T13:10:47+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/delarsrapport-januari-juni-2011-1412529-0 2022-10-31T13:10:19+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/delarsrapport-januari-september-2011-1412515-0 2022-10-31T13:10:11+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-delarsrapport-januari-mars-2012-1412490-0 2022-10-31T13:10:02+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-delarsrapport-andra-kvartalet-2012-1412470-0 2022-10-31T13:09:54+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/delarsrapport-januari-september-2012-1412463-0 2022-10-31T13:09:46+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-publicerar-resultaten-forsta-kvartalet-2013-1412434-0 2022-10-31T13:09:32+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-publicerar-resultaten-det-andra-kvartalet-2013-1412420-0 2022-10-31T13:09:23+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-publicerar-resultaten-det-tredje-kvartalet-2013-1412402-0 2022-10-31T13:09:13+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-publicerar-resultaten-det-forsta-kvartalet-2014-1412358-0 2022-10-31T13:09:03+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-publicerar-resultaten-det-andra-kvartalet-2014-1412341-0 2022-10-31T13:08:47+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-publicerar-resultaten-det-tredje-kvartalet-2014-1412328-0 2022-10-31T13:08:38+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-publicerar-sin-rapport-forsta-kvartalet-2015-1412310-0 2022-10-31T13:08:29+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-publicerar-sin-rapport-det-andra-kvartalet-2015-hojer-utsikterna-1412296-0 2022-10-31T13:08:20+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-publicerar-sin-rapport-det-tredje-kvartalet-2015-1412286-0 2022-10-31T13:08:12+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-publicerar-sin-rapport-forsta-kvartalet-2016-1412851-0 2022-10-31T13:08:01+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-publicerar-sin-rapport-det-andra-kvartalet-2016-1424404-0 2022-10-31T13:07:53+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobitm-publicerar-sin-rapport-det-tredje-kvartalet-2016-uppjusterar-utsikter-0 2022-10-31T13:07:44+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-publicerar-sin-rapport-det-forsta-kvartalet-2017-1487410-0 2022-10-31T13:07:34+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobitm-publicerar-sin-rapport-det-andra-kvartalet-2017-1508760-0 2022-10-31T13:07:25+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobitm-publicerar-sin-rapport-det-tredje-kvartalet-2017-1527208-0 2022-10-31T13:06:48+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobitm-publicerar-rapporten-det-forsta-kvartalet-2018-1571518-0 2022-10-31T13:06:24+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobitm-publicerar-rapporten-det-andra-kvartalet-2018-1599208-0 2022-10-31T13:06:09+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobitm-publicerar-rapporten-det-tredje-kvartalet-2018-1628775-0 2022-10-31T13:05:57+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-publicerar-delarsrapporten-det-forsta-kvartalet-2019-1680655-0 2022-10-31T13:05:47+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-publicerar-delarsrapporten-det-andra-kvartalet-2019-1708491-0 2022-10-31T13:05:29+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-publicerar-delarsrapporten-det-tredje-kvartalet-2019-1740746-0 2022-10-31T13:05:20+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-publicerar-delarsrapporten-det-forsta-kvartalet-2020-1805296-0 2022-10-31T13:05:02+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-publicerar-delarsrapporten-det-andra-kvartalet-2020-1826264-0 2022-10-31T13:04:53+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-publicerar-delarsrapporten-det-tredje-kvartalet-2020-1855863-0 2022-10-31T13:04:39+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-publicerar-rapport-forsta-kvartalet-2021-1913209-0 2022-10-31T13:04:28+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-publicerar-rapport-andra-kvartalet-2021-1934390-0 2022-10-31T13:04:18+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-publicerar-rapport-tredje-kvartalet-2021-1956948-0 2022-10-31T13:04:07+01:00 0.5 https://www.sobi.com/en/press-releases/biovitrums-interim-report-january-march-2007-1412760-0 2022-10-31T13:01:45+01:00 0.5 https://www.sobi.com/en/press-releases/biovitrum-interim-report-january-1-june-30-2007-1412744-0 2022-10-31T13:01:35+01:00 0.5 https://www.sobi.com/en/press-releases/biovitrum-interim-report-january-1-september-30-2007-1412848-0 2022-10-31T13:01:26+01:00 0.5 https://www.sobi.com/en/press-releases/biovitrum-interim-report-january-1-march-31-2008-1412820-0 2022-10-31T13:01:11+01:00 0.5 https://www.sobi.com/en/press-releases/biovitrum-interim-report-january-1-june-30-2008-1412740-0 2022-10-31T13:00:58+01:00 0.5 https://www.sobi.com/en/press-releases/biovitrum-interim-report-january-1-september-30-2008-1412731-0 2022-10-31T13:00:46+01:00 0.5 https://www.sobi.com/en/press-releases/biovitrum-interim-report-1st-january-31st-march-2009-1412709-0 2022-10-31T13:00:34+01:00 0.5 https://www.sobi.com/en/press-releases/interim-report-1st-april-30th-june-2009-1412697-0 2022-10-31T13:00:22+01:00 0.5 https://www.sobi.com/en/press-releases/biovitrum-interim-report-january-1st-september-30th-2009-1412687-0 2022-10-31T13:00:05+01:00 0.5 https://www.sobi.com/en/press-releases/interim-financial-report-period-1-january-31-march-2010-1412619-0 2022-10-31T12:59:52+01:00 0.5 https://www.sobi.com/en/press-releases/interim-financial-report-period-1st-april-30th-june-2010-1412600-0 2022-10-31T12:59:41+01:00 0.5 https://www.sobi.com/en/press-releases/interim-financial-report-period-1st-january-30th-september-2010-1412589-0 2022-10-31T12:59:31+01:00 0.5 https://www.sobi.com/en/press-releases/interim-report-january-march-2011-1412551-0 2022-10-31T12:59:18+01:00 0.5 https://www.sobi.com/en/press-releases/interim-report-january-june-2011-1412526-0 2022-10-31T12:59:04+01:00 0.5 https://www.sobi.com/en/press-releases/interim-report-january-september-2011-1412519-0 2022-10-31T12:26:43+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-interim-report-january-march-2012-1412489-0 2022-10-31T12:26:33+01:00 0.5 https://www.sobi.com/en/press-releases/sobiinterim-report-second-quarter-2012-1412471-0 2022-10-31T12:26:24+01:00 0.5 https://www.sobi.com/en/press-releases/interim-report-january-september-2012-1412460-0 2022-10-31T12:26:14+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-publishes-report-first-quarter-2013-1412436-0 2022-10-31T12:26:00+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-publishes-report-second-quarter-2013-1412423-0 2022-10-31T12:25:51+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-publishes-report-third-quarter-2013-1412404-0 2022-10-31T12:25:42+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-publishes-report-first-quarter-2014-1412359-0 2022-10-31T12:25:33+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-publishes-report-second-quarter-2014-1412340-0 2022-10-31T12:25:24+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-publishes-report-third-quarter-2014-1412332-0 2022-10-31T12:25:14+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-publishes-its-report-first-quarter-2015-1412314-0 2022-10-31T12:25:04+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-publishes-its-report-second-quarter-2015-raises-guidance-1412297-0 2022-10-31T12:24:55+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-publishes-its-report-third-quarter-2015-1412287-0 2022-10-31T12:24:46+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-publishes-its-report-first-quarter-2016-1412852-0 2022-10-31T12:24:35+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-publishes-its-report-second-quarter-2016-1424395-0 2022-10-31T12:24:26+01:00 0.5 https://www.sobi.com/en/press-releases/sobitm-publishes-its-report-third-quarter-2016-raises-guidance-1439585-0 2022-10-31T12:24:17+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-publishes-its-report-first-quarter-2017-1487405-0 2022-10-31T12:24:09+01:00 0.5 https://www.sobi.com/en/press-releases/sobitm-publishes-its-report-second-quarter-2017-1508759-0 2022-10-31T12:24:00+01:00 0.5 https://www.sobi.com/en/press-releases/sobitm-publishes-its-report-third-quarter-2017-1527216-0 2022-10-31T12:23:37+01:00 0.5 https://www.sobi.com/en/press-releases/sobitm-publishes-report-first-quarter-2018-1571514-0 2022-10-31T12:23:23+01:00 0.5 https://www.sobi.com/en/press-releases/sobitm-publishes-report-second-quarter-2018-1599205-0 2022-10-31T12:23:15+01:00 0.5 https://www.sobi.com/en/press-releases/sobitm-publishes-report-third-quarter-2018-1628770-0 2022-10-31T12:23:05+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-publishes-report-first-quarter-2019-1680642-0 2022-10-31T12:22:47+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-publishes-report-second-quarter-2019-1708490-0 2022-10-31T12:22:38+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-publishes-report-third-quarter-2019-1740747-0 2022-10-31T12:22:19+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-publishes-report-first-quarter-2020-1805291-0 2022-10-31T12:22:10+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-publishes-report-second-quarter-2020-1826263-0 2022-10-31T12:22:01+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-publishes-report-third-quarter-2020-1855862-0 2022-10-31T12:21:48+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-publishes-report-first-quarter-2021-1913212-0 2022-10-31T12:21:39+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-publishes-report-second-quarter-2021-1934386-0 2022-10-31T12:21:30+01:00 0.5 https://www.sobi.com/en/press-releases/sobi-publishes-report-third-quarter-2021-1956951-0 2022-10-31T12:21:21+01:00 0.5 https://www.sobi.com/sv/pressmeddelanden/inbjudan-sobis-delarsrapport-tredje-kvartalet-2022-2059134 2022-10-14T15:00:17+02:00 0.5 https://www.sobi.com/en/press-releases/invitation-sobis-q3-2022-report-2059137 2022-10-14T15:00:17+02:00 0.5 https://www.sobi.com/en/press-releases/fda-grants-priority-review-efanesoctocog-alfa-people-haemophilia-2047525 2022-10-03T11:45:55+02:00 0.5 https://www.sobi.com/en/press-releases/board-directors-exercises-authorisation-repurchase-shares-purpose-securing-2 2022-10-03T11:45:55+02:00 0.5 https://www.sobi.com/en/press-releases/new-real-world-data-shows-significantly-improved-prophylactic-effectiveness-patients 2022-10-03T11:45:55+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/fda-beviljar-efanesoctocog-alfa-prioriterad-granskning-behandling-av-personer-med 2022-10-03T11:45:55+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/styrelsen-utnyttjar-aterkopsbemyndigande-sakerstallande-av-bolagets-ataganden-4 2022-10-03T11:45:55+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/nya-real-world-data-visar-pa-signifikant-battre-effektivitet-hos-patienter 2022-10-03T11:45:55+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/andring-av-antalet-aktier-och-roster-i-swedish-orphan-biovitrum-ab-publ-2055455 2022-09-30T08:00:25+02:00 0.5 https://www.sobi.com/en/press-releases/new-number-shares-and-votes-swedish-orphan-biovitrum-ab-publ-2055453 2022-09-30T08:00:24+02:00 0.5 https://www.sobi.com/en/press-releases/loncastuximab-tesirine-receives-positive-chmp-opinion-treatment-relapsed-or 2022-09-16T13:15:23+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/loncastuximab-tesirine-far-positivt-chmp-utlatande-behandling-av-recidiverande 2022-09-16T13:15:23+02:00 0.5 https://www.sobi.com/en/press-releases/pivotal-data-demonstrate-once-weekly-efanesoctocog-alfa-provides-superior-bleed 2022-07-11T11:16:21+02:00 0.5 https://www.sobi.com/en/press-releases/invitation-sobis-q2-2022-report-2035379 2022-07-11T11:16:21+02:00 0.5 https://www.sobi.com/en/press-releases/sobi-license-loncastuximab-tesirine-adc-therapeutics-2035301 2022-07-11T11:16:21+02:00 0.5 https://www.sobi.com/en/press-releases/sobi-present-new-data-isth-2022-2031947 2022-07-11T11:16:21+02:00 0.5 https://www.sobi.com/en/press-releases/new-data-reinforce-robust-efficacy-and-safety-profile-aspaveliempaveli-pegcetacoplan 2022-07-11T11:16:21+02:00 0.5 https://www.sobi.com/en/press-releases/first-patient-dosed-valiant-phase-3-study-pegcetacoplan-ic-mpgn-and-c3g-rare-kidney 2022-07-11T11:16:21+02:00 0.5 https://www.sobi.com/en/press-releases/fda-grants-efanesoctocog-alfa-breakthrough-therapy-designation-haemophilia-2025889 2022-07-11T11:16:21+02:00 0.5 https://www.sobi.com/en/press-releases/sobi-present-new-data-both-pnh-and-itp-2022-eha-congress-2020822 2022-07-11T11:16:21+02:00 0.5 https://www.sobi.com/en/press-releases/bulletin-swedish-orphan-biovitrum-sobirs-annual-general-meeting-agm-2019385 2022-07-11T11:16:21+02:00 0.5 https://www.sobi.com/en/press-releases/invitation-sobis-q1-2022-report-2010729 2022-07-11T11:16:21+02:00 0.5 https://www.sobi.com/en/press-releases/notice-annual-general-meeting-swedish-orphan-biovitrum-ab-publ-2006451 2022-07-11T11:16:21+02:00 0.5 https://www.sobi.com/en/press-releases/sobi-cease-refacto-manufacturing-first-quarter-2024-2002080 2022-07-11T11:16:21+02:00 0.5 https://www.sobi.com/en/press-releases/gamifant-approved-china-treatment-primary-haemophagocytic-lymphohistiocytosis 2022-07-11T11:16:21+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/data-fran-en-pivotal-studie-visar-att-efanesoctocog-alfa-administrerad-en-gang-i 2022-07-11T11:16:21+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/inbjudan-sobis-delarsrapport-andra-kvartalet-2022-2035373 2022-07-11T11:16:21+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-licensierar-loncastuximab-tesirine-fran-adc-therapeutics-2035299 2022-07-11T11:16:21+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-presenterar-nya-data-vid-isth-2022-2031948 2022-07-11T11:16:21+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/nya-data-pa-eha2022-starker-aspaveliempavelis-pegcetacoplan-robusta-effekt-och 2022-07-11T11:16:21+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/forsta-patienten-doserad-i-fas-3-studien-valiant-med-pegcetacoplan-vid-ic-mpgn-och 2022-07-11T11:16:21+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/fda-tilldelar-efanesoctocog-alfa-genombrottsstatus-hemofili-2025887 2022-07-11T11:16:21+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-presenterar-nya-data-om-bade-pnh-och-itp-pa-eha-kongressen-2022-2020823 2022-07-11T11:16:21+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/kommunike-fran-swedish-orphan-biovitrums-sobir-arsstamma-2019384 2022-07-11T11:16:21+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/inbjudan-sobis-delarsrapport-forsta-kvartalet-2022-2010730 2022-07-11T11:16:21+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/kallelse-till-arsstamma-i-swedish-orphan-biovitrum-ab-publ-2006453 2022-07-11T11:16:21+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/sobi-kommer-att-upphora-med-refacto-tillverkningen-forsta-kvartalet-2024-2002082 2022-07-11T11:16:21+02:00 0.5 https://www.sobi.com/sv/pressmeddelanden/gamifantr-godkant-i-kina-behandling-av-primar-hemofagocyterande-lymfohistiocytos 2022-07-11T11:16:21+02:00 0.5